# 2026年1月17日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. CBX3在血行转移过程中赋予铁死亡抵抗性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540451)
**期刊：** Journal of hematology & oncology
**PMID：** 41540451
**DOI：** 10.1186/s13045-025-01777-0

### 第一部分 原文与翻译

**英文原标题：** CBX3 confers ferroptosis resistance during blood-borne metastasis.

> **英文摘要：**
> The survival mechanisms of circulating tumor cells (CTCs) remain poorly understood while these rare cell populations transit through the blood stream and colonize distant organs including the brain. Using single-cell RNA-seq of microfluidically-enriched CTCs and patient-matched brain metastatic tumor cells of lung adenocarcinoma (LUAD), we revealed CTC-selective upregulation of core gene signatures associated with ferroptosis. The malignancy of CTCs was confirmed through comparative genomic instability and copy number variation (CNV) analyses of paired CTCs and metastatic tumor cells using both transcriptomic and whole-exome sequencing. Among the transcription factors elevated in CTCs, Chromobox 3 (CBX3) was the top hit, which was tightly correlated with GPX4 expression. Functionally, CBX3 co-operated with EP300 to protect CTCs from ferroptosis by upregulating GPX4 expression. Genetic depletion of CBX3 triggered ferroptosis and substantially reduced tumor细胞 survival and invasiveness in two independent cancer cell models. Conversely, CBX3 overexpression was sufficient to promote tumor growth, migration, and invasion in vitro, and metastatic progression in vivo. Clinically, CBX3 expression was significantly correlated with TNM stage and was predictive of both progression-free interval and overall survival in LUAD. In a prospective cohort of LUAD and melanoma patients, CTCs co-expressing CBX3 and GPX4 were selectively elevated in the blood samples of metastatic cases compared to the non-metastatic group, highlighting the clinical association between ferroptosis-resistant CTCs and metastatic progression.

> **中文摘要：**
> 循环肿瘤细胞（CTCs）在血液中迁移并定植于包括大脑在内的远处器官时，其生存机制仍知之甚少。通过对微流控富集的CTCs和患者匹配的肺腺癌（LUAD）脑转移肿瘤细胞进行单细胞RNA测序，我们揭示了CTCs选择性上调了与铁死亡相关的核心基因特征。通过转录组和全外显子组测序对配对的CTCs和转移性肿瘤细胞进行比较基因组不稳定性和拷贝数变异（CNV）分析，证实了CTCs的恶性程度。在CTCs中上调的转录因子中，Chromobox 3（CBX3）是首要发现，其表达与GPX4紧密相关。在功能上，CBX3与EP300协同作用，通过上调GPX4表达来保护CTCs免于铁死亡。在两个独立的癌细胞模型中，基因敲除CBX3会引发铁死亡，并显著降低肿瘤细胞的存活和侵袭能力。相反，CBX3过表达足以在体外促进肿瘤生长、迁移和侵袭，并在体内促进转移进展。临床上，CBX3表达与TNM分期显著相关，并能预测LUAD患者的无进展间期和总生存期。在一项针对LUAD和黑色素瘤患者的前瞻性队列中，与非转移组相比，转移病例血液样本中共同表达CBX3和GPX4的CTCs选择性升高，这突显了具有铁死亡抵抗性的CTCs与转移进展之间的临床关联。

### 第二部分 AI 大师评价

本研究旨在探索循环肿瘤细胞（CTCs）在血行转移过程中的生存机制。通过整合单细胞RNA测序、基因组学分析和功能实验，研究发现转录因子CBX3通过与EP300协同上调GPX4表达，赋予CTCs铁死亡抵抗性，这是其成功转移的关键。该研究创新性地将表观遗传调控因子CBX3与铁死亡这一细胞死亡途径联系起来，揭示了CTCs在血液微环境中的新生存策略，并提供了潜在的预后标志物和治疗靶点。然而，研究主要聚焦于肺腺癌和黑色素瘤模型，其机制在其他癌种中的普适性有待验证，且CBX3-EP300-GPX4轴的具体分子调控细节仍需进一步阐明。

---

## 2. 肿瘤学中的微小RNA：人工智能时代的转化视角

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540122)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41540122
**DOI：** 10.1038/s41571-025-01114-x

### 第一部分 原文与翻译

**英文原标题：** MicroRNAs in oncology: a translational perspective in the era of AI.

> **英文摘要：**
> Over the past three decades, knowledge of microRNA (miRNA) biology has advanced from the initial discovery of their regulatory functions to the finding of abnormal activity in leukaemias, and then to a comprehensive understanding of the roles of miRNAs in both normal physiology and most diseases, with cancer being extensively studied. miRNA dysregulation contributes to tumorigenesis, with certain miRNAs acting as either tumour suppressors or oncogenic factors in a context-dependent manner. A subset of miRNAs have shown promise as tumour biomarkers and therapeutic targets in preclinical studies, with several miRNA-based diagnostic tools and treatments progressing to clinical trials. Artificial intelligence (AI) and machine learning techniques began to be introduced into cancer research and oncology a decade ago and are now on the verge of revolutionizing biomarker identification and clinical trials. In this Review, we highlight important roles of miRNAs in cancer biology and their potential as diagnostic tools and therapeutic targets. In particular, we discuss emerging challenges and opportunities presented by AI-driven data analysis and combinatorial strategies, and how advances in these areas have addressed previous doubts on the clinical translation of miRNA-based biomarkers and therapeutics.

> **中文摘要：**
> 在过去的三十年中，对微小RNA（miRNA）生物学的认识已从最初发现其调控功能，进展到发现其在白血病中的异常活性，进而全面理解了miRNA在正常生理和大多数疾病（其中癌症得到了广泛研究）中的作用。miRNA失调促进了肿瘤发生，某些miRNA根据具体情境发挥抑癌因子或致癌因子的作用。一部分miRNA在临床前研究中显示出作为肿瘤生物标志物和治疗靶点的潜力，一些基于miRNA的诊断工具和治疗方法已进入临床试验阶段。人工智能（AI）和机器学习技术大约十年前开始被引入癌症研究和肿瘤学领域，如今正处于彻底变革生物标志物识别和临床试验的边缘。在这篇综述中，我们重点阐述了miRNA在癌症生物学中的重要作用及其作为诊断工具和治疗靶点的潜力。我们特别讨论了由AI驱动的数据分析和组合策略所带来的新挑战与机遇，以及这些领域的进展如何解决了先前对基于miRNA的生物标志物和治疗手段临床转化的疑虑。

### 第二部分 AI 大师评价

本文是一篇综述，核心目的是从转化医学视角，系统阐述miRNA在肿瘤学中的研究进展，并重点探讨AI技术如何赋能该领域。文章方法上，回顾了miRNA从基础生物学发现到临床应用的三十年历程，并前瞻性地分析了AI在生物标志物识别和临床试验设计中的革命性潜力。其创新性在于，将经典的miRNA研究与前沿的AI技术相结合，为克服miRNA临床转化的瓶颈提供了新的思路和策略。局限性在于，作为一篇前瞻性综述，其讨论的AI应用潜力大多仍处于早期阶段，具体的技术路径和临床验证结果尚待未来研究证实。

---

## 3. CD4 T细胞介导BCMA CAR-T细胞疗法后CAR-T细胞相关免疫相关不良事件。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540109)
**期刊：** Nature medicine
**PMID：** 41540109
**DOI：** 10.1038/s41591-025-04121-8

### 第一部分 原文与翻译

**英文原标题：** CD4 T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.

> **英文摘要：**
> B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of multiple myeloma but can cause unique toxicities, including cranial nerve palsy, parkinsonism and enterocolitis, which we refer to collectively as CAR T cell therapy-associated immune-related adverse events (CirAEs). Among 198 patients treated with ciltacabtagene autoleucel or idecabtagene vicleucel (June 2021-December 2024), 27 (13.6%) developed CirAEs. This included one remarkable case with three distinct CirAEs in association with an extreme CD4 CAR T cell expansion (peak lymphocytes: 197 × 10 per microliter), which was abrogated in vitro by CCR5 inhibition. CirAEs were associated with significantly higher non-relapse mortality (hazard ratio = 5.2, P = 0.006), and independent risk factors included ciltacabtagene autoleucel (odds ratio = 4.5, P = 0.058), peak absolute lymphocyte count ≥ 2.4 × 10 per microliter in the first 14 days post-infusion (odds ratio = 4.3, P < 0.001) and apheresis CD4:CD8 ratio > 1 (odds ratio = 2.6, P = 0.048). We identified marked CD4 CAR T cell infiltration in all available CirAE tissues, including cerebrospinal fluid during neurologic CirAEs, implicating CD4 CAR T cell therapy as a key mediator of these toxicities.

> **中文摘要：**
> 靶向B细胞成熟抗原（BCMA）的嵌合抗原受体（CAR）T细胞疗法已彻底改变了多发性骨髓瘤的治疗，但可能引起独特的毒性，包括颅神经麻痹、帕金森综合征和肠炎，我们将其统称为CAR-T细胞疗法相关免疫相关不良事件（CirAEs）。在198名接受西达基奥仑赛或伊基奥仑赛治疗的患者（2021年6月至2024年12月）中，27名（13.6%）发生了CirAEs。其中包括一例显著病例，该病例出现了三种不同的CirAEs，并与极端的CD4 CAR T细胞扩增相关（淋巴细胞峰值：197×10^9/升），这种扩增在体外可通过抑制CCR5来消除。CirAEs与显著更高的非复发死亡率相关（风险比=5.2，P=0.006），其独立风险因素包括使用西达基奥仑赛（比值比=4.5，P=0.058）、输注后14天内峰值绝对淋巴细胞计数≥2.4×10^9/升（比值比=4.3，P<0.001）以及单采时CD4:CD8比值>1（比值比=2.6，P=0.048）。我们在所有可获得的CirAE组织中，包括神经性CirAEs期间的脑脊液中，均发现了显著的CD4 CAR T细胞浸润，这表明CD4 CAR T细胞是这些毒性的关键介导者。

### 第二部分 AI 大师评价

本研究旨在阐明BCMA CAR-T疗法后特定免疫相关不良事件（CirAEs）的机制与风险因素。通过对198名患者的回顾性分析，研究首次将CD4 CAR-T细胞明确鉴定为CirAEs（如神经毒性和肠炎）的关键介导者，并揭示了其与极端淋巴细胞扩增的关联。研究创新性地通过体外CCR5抑制实验提供了潜在干预靶点，并量化了多个临床风险因素（如特定CAR-T产品、早期淋巴细胞峰值、基线CD4/CD8比），对患者风险分层和毒性管理具有重要临床指导价值。局限性在于其观察性研究设计，因果关系的确立及CCR5抑制的临床转化仍需前瞻性研究验证。

---

## 4. 多发性骨髓瘤中针对GPRC5D靶向T细胞衔接器的多模式抗原逃逸。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540108)
**期刊：** Nature medicine
**PMID：** 41540108
**DOI：** 10.1038/s41591-025-04175-8

### 第一部分 原文与翻译

**英文原标题：** Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

> **英文摘要：**
> Tumor-intrinsic adaptations with emerging resistant clones following T cell-targeted immunotherapies pose a major barrier to durable remissions in multiple myeloma. Through integrated genomic, transcriptomic and epigenomic interrogation of clonal plasma cells, we observed antigenic drift in 68.4% of relapsed cases following anti-GPRC5D T cell-engager (TCE) therapy (n = 21). These escape events were driven by three distinct mutational mechanisms involving (1) focal to large biallelic deletions at the GPRC5D gene locus; (2) monoallelic deletion coupled with GPRC5D single-nucleotide variants or insertions/deletions (indels) on the remaining allele; as well as (3) epigenetic GPRC5D promoter/enhancer silencing. Beyond biallelic deletions resulting in complete antigenic loss, we demonstrate that GPRC5D single-nucleotide variants and indels mutate anti-GPRC5D TCE-binding epitopes or more commonly affect G-protein-coupled receptor family conserved motifs critical for protein membrane trafficking resulting in endoplasmic reticulum GPRC5D trapping. Multiple subclones bearing distinct genomic alterations at GPRC5D locus co-emerged within individual cases, depicting their convergent evolutionary trajectories. Of note, anti-GPRC5D TCEs with varying epitope specificity, affinity and valency differentially targeted mutant subclones, underscoring their nonredundant functional roles in overcoming resistance.

> **中文摘要：**
> T细胞靶向免疫治疗后，肿瘤内在的适应性变化及耐药克隆的出现是多发性骨髓瘤获得持久缓解的主要障碍。通过对克隆性浆细胞进行整合的基因组、转录组和表观基因组分析，我们观察到在接受抗GPRC5D T细胞衔接器治疗后复发的病例中，有68.4%发生了抗原漂移。这些逃逸事件由三种不同的突变机制驱动，包括：(1) GPRC5D基因位点发生局灶性至大片段双等位基因缺失；(2) 单等位基因缺失，同时剩余等位基因上伴有GPRC5D单核苷酸变异或插入/缺失；以及(3) GPRC5D启动子/增强子的表观遗传沉默。除了导致完全抗原丢失的双等位基因缺失外，我们还证明GPRC5D单核苷酸变异和插入/缺失会突变抗GPRC5D TCE的结合表位，或者更常见的是影响对蛋白质膜转运至关重要的G蛋白偶联受体家族保守基序，从而导致GPRC5D在内质网滞留。在单个病例中，携带GPRC5D位点不同基因组改变的多个亚克隆共同出现，描绘了它们趋同的进化轨迹。值得注意的是，具有不同表位特异性、亲和力和价态的抗GPRC5D TCE对突变亚克隆的靶向作用存在差异，这突显了它们在克服耐药性方面非冗余的功能作用。

### 第二部分 AI 大师评价

本研究旨在系统揭示多发性骨髓瘤对GPRC5D靶向T细胞衔接器产生耐药的分子机制。研究者采用整合多组学方法，在复发患者克隆性浆细胞中，首次全面描绘了由基因缺失、点突变/插入缺失及表观沉默驱动的多模式抗原逃逸全景图。其核心创新在于不仅鉴定了导致抗原完全丢失的机制，更深入阐明了单核苷酸变异通过干扰蛋白转运导致内质网滞留这一更隐蔽的逃逸途径，并揭示了不同TCE设计在靶向突变克隆时的功能差异，为开发克服耐药的下一代疗法提供了关键理论基础。然而，研究样本量相对有限，且主要聚焦于肿瘤细胞内在机制，未来需在更大队列中验证，并探索肿瘤微环境等外在因素的作用。

---

## 5. STK38介导的Hedgehog通路反馈环调控肾乳头状癌肿瘤异质性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540036)
**期刊：** Cell death & disease
**PMID：** 41540036
**DOI：** 10.1038/s41419-025-08225-4

### 第一部分 原文与翻译

**英文原标题：** STK38-mediated feedback loop regulation of the hedgehog pathway governing tumor heterogeneity in renal papillary carcinoma.

> **英文摘要：**
> Papillary renal cell carcinoma (pRCC) is characterized by marked intratumoral heterogeneity, which contributes to therapeutic resistance and disease progression. In this study, we identify STK38 as a key regulator of tumor heterogeneity in pRCC, functioning through non-canonical activation of the Hedgehog (Hh) signaling pathway. STK38 interacts with both KIF7 and GSK3β to promote Hh signaling by facilitating KIF7 ciliary localization and reprogramming GSK3β substrate selectivity, leading to GLI1 stabilization and β-catenin suppression. Moreover, GLI1 directly enhances STK38 transcription, establishing a positive feedback loop that reinforces pathway activation. Notably, depletion of STK38 sensitizes tumor cells to a NETosis-like chromatin release process (tNET release), a form of stress-induced nuclear expulsion associated with immune evasion and metastatic potential. Given the potential pro-metastatic consequences of STK38 inhibition, we instead targeted its downstream effector GLI1 using Glabrescione B, which potently suppressed tumor growth and induced apoptosis in both xenograft and patient-derived organoid models, particularly in STK38-high tumors. These findings position STK38 as a critical modulator of pRCC heterogeneity and support GLI1 inhibition as a promising strategy to disrupt oncogenic signaling while minimizing adverse effects.

> **中文摘要：**
> 乳头状肾细胞癌（pRCC）以显著的瘤内异质性为特征，这导致了治疗抵抗和疾病进展。本研究确定STK38是pRCC肿瘤异质性的关键调节因子，其通过非经典方式激活Hedgehog（Hh）信号通路发挥作用。STK38与KIF7和GSK3β相互作用，通过促进KIF7的纤毛定位并重编程GSK3β的底物选择性来促进Hh信号传导，从而导致GLI1稳定化和β-catenin抑制。此外，GLI1直接增强STK38的转录，建立了一个正反馈循环，从而加强了通路的激活。值得注意的是，STK38的耗竭使肿瘤细胞对一种类似NETosis的染色质释放过程（tNET释放）敏感，这是一种与免疫逃逸和转移潜能相关的应激诱导的核排出形式。考虑到抑制STK38可能带来的促转移后果，我们转而使用Glabrescione B靶向其下游效应因子GLI1，该药物在异种移植和患者来源的类器官模型中均能有效抑制肿瘤生长并诱导细胞凋亡，尤其是在STK38高表达的肿瘤中。这些发现确立了STK38作为pRCC异质性的关键调节因子，并支持GLI1抑制作为一种有前景的策略，可在最小化不良反应的同时破坏致癌信号传导。

### 第二部分 AI 大师评价

本研究旨在阐明肾乳头状癌（pRCC）肿瘤异质性的调控机制，并探索潜在的治疗靶点。研究者通过分子生物学方法，揭示了STK38通过非经典方式激活Hedgehog通路，并与GLI1形成正反馈循环，驱动肿瘤异质性和进展。创新性地发现STK38缺失会诱导类似NETosis的染色质释放（tNET释放），提示其抑制可能带来促转移风险，从而巧妙地转向靶向下游GLI1，并在临床前模型中验证了GLI1抑制剂Glabrescione B的有效性。然而，研究主要基于临床前模型，其结论在人体内的转化效果、长期安全性以及tNET释放的具体免疫学后果仍需进一步探索。

---

## 6. 解码恶性肿瘤中的neddylation：分子机制、生物学功能、治疗耐药性与临床潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540013)
**期刊：** Cell death & disease
**PMID：** 41540013
**DOI：** 10.1038/s41419-025-08255-y

### 第一部分 原文与翻译

**英文原标题：** Decoding neddylation in malignancies: molecular mechanisms, biological functions, therapeutic resistance, and clinical potential.

> **英文摘要：**
> Neddylation, a protein post-translational modification, regulates diverse molecular biological processes in tumors, governing protein stability, function, subcellular localization, and transcriptional activity. Thus, it plays an essential role in sustaining tumorigenicity and the hallmarks of cancer. In tumors, neddylation is triggered by various forms of cellular stress, involving hypoxia, oxidative stress, and tumor metabolites, all of which drive tumor initiation and progression. This review explores the critical regulatory mechanisms and pathological features of the neddylation cascade in terms of tumor malignant evolution and therapeutic resistance. Additionally, it examines therapeutic strategies targeting NEDD8 modification, offering novel avenues for innovative cancer treatments by disrupting this dynamic, reversible modification process.

> **中文摘要：**
> Neddylation作为一种蛋白质翻译后修饰，调控肿瘤中多种分子生物学过程，包括蛋白质稳定性、功能、亚细胞定位和转录活性。因此，它在维持肿瘤发生能力和癌症特征方面发挥着至关重要的作用。在肿瘤中，neddylation由多种形式的细胞应激触发，包括缺氧、氧化应激和肿瘤代谢物，所有这些都驱动肿瘤的发生和进展。本综述从肿瘤恶性演进和治疗耐药性的角度，探讨了neddylation级联反应的关键调控机制和病理特征。此外，文章还审视了靶向NEDD8修饰的治疗策略，通过干扰这一动态、可逆的修饰过程，为创新癌症治疗提供了新途径。

### 第二部分 AI 大师评价

这篇综述旨在系统解码neddylation修饰在恶性肿瘤中的核心作用。其方法是通过整合现有研究，深入剖析该修饰的分子调控机制、生物学功能及其在肿瘤演进和耐药中的病理特征。核心发现是，neddylation作为关键的应激响应通路，通过调控蛋白质功能驱动肿瘤恶性表型，而靶向此通路则展现出克服治疗耐药的新策略。其创新性在于将基础分子机制与临床治疗潜力紧密结合，为开发新型抗癌药物提供了清晰的理论框架；局限性在于作为综述，其结论主要基于已有研究整合，仍需更多前瞻性实验和临床数据来验证相关治疗策略的有效性。

---

## 7. 芳烃受体：结构、信号传导、生理与病理

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540003)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41540003
**DOI：** 10.1038/s41392-025-02500-8

### 第一部分 原文与翻译

**英文原标题：** The aryl hydrocarbon receptor: structure, signaling, physiology and pathology.

> **英文摘要：**
> The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor of the bHLH/PAS protein family. In this review, we explore the multifaceted roles of AHR in both health and disease, tracing its recognition as a xenobiotic sensor and a central regulator of physiological homeostasis. We begin by recounting six decades of discoveries that have shaped our understanding of AHR, from its canonical function in environmental sensing to its critical roles in development, immune regulation, barrier tissue integrity, and host-microbe interactions. We detail recent structural breakthroughs that have illuminated the ligand-binding mechanisms and regulation of AHR, providing key insights into its activation and transcriptional control. We also highlight the diversity of AHR ligands, ranging from environmental toxins to microbial and dietary metabolites of tryptophan, and their context-dependent effects on AHR activation through the canonical pathway and noncanonical signaling mechanisms. We examine the involvement of AHR in pathologies such as cancer and autoimmune and inflammatory diseases and its potential as a therapeutic target. Finally, emphasis is placed on recent advances and future developments in drug design, aiming to develop modulators with clinical efficacy. This comprehensive synthesis underscores the dual role of AHR as a master integrator of both environmental and endogenous cues. Placing AHR within broader frameworks, such as the exposome, opens new avenues for therapeutic innovation and more effective strategies for disease prevention.

> **中文摘要：**
> 芳烃受体（AHR）是bHLH/PAS蛋白家族中的一种配体依赖性转录因子。在这篇综述中，我们探讨了AHR在健康和疾病中的多方面作用，追溯了其作为外源性物质传感器和生理稳态核心调节因子的认识历程。我们首先回顾了六十年来塑造我们对AHR理解的一系列发现，从其环境感知的经典功能，到其在发育、免疫调节、屏障组织完整性以及宿主-微生物相互作用中的关键作用。我们详述了近期阐明AHR配体结合机制和调控的结构突破，这为其激活和转录控制提供了关键见解。我们还强调了AHR配体的多样性，从环境毒素到微生物和膳食来源的色氨酸代谢物，以及它们通过经典途径和非经典信号机制对AHR激活产生的环境依赖性效应。我们探讨了AHR在癌症、自身免疫性疾病和炎症性疾病等病理过程中的参与及其作为治疗靶点的潜力。最后，重点阐述了药物设计的最新进展和未来发展，旨在开发具有临床疗效的调节剂。这一全面的综述强调了AHR作为环境和内源性信号主整合器的双重角色。将AHR置于更广泛的框架中，如暴露组学，为治疗创新和更有效的疾病预防策略开辟了新途径。

### 第二部分 AI 大师评价

本文是一篇关于芳烃受体（AHR）的全面综述，旨在系统整合其结构、信号、生理与病理功能的最新认知。文章采用文献回顾法，系统梳理了六十年的研究历程，重点突出了近期结构生物学突破对理解AHR配体结合与激活机制的贡献，并广泛探讨了从环境毒素到内源性色氨酸代谢物等多样配体的作用。其核心创新在于将AHR定位为整合环境与内源性信号的主调节器，并前瞻性地将其置于“暴露组”框架下，为疾病治疗与预防提供了新的理论视角和药物研发方向。作为一篇综述，其局限性在于主要基于现有文献进行综合评述，未报告新的原始实验数据。

---

## 8. 双磷酸核苷酸酶1通过STUB1介导的LIMA1去稳定化促进三阴性乳腺癌进展及多西他赛耐药

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540000)
**期刊：** Cell death & disease
**PMID：** 41540000
**DOI：** 10.1038/s41419-025-08245-0

### 第一部分 原文与翻译

**英文原标题：** Bisphosphate nucleotidase 1 promotes progression and docetaxel resistance in triple-negative breast cancer via STUB1-mediated destabilization of LIMA1.

> **英文摘要：**
> Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer without effective targeted therapies. Integrative analysis of transcriptomic and proteomic datasets of TNBC in our center revealed that bisphosphate nucleotidase 1 (BPNT1), a member of inositol monophosphatase superfamily with poorly characterized functional and mechanistic roles in human cancer, was abnormally upregulated in TNBC and its high expression was associated with poor patient prognosis. Loss- and gain-of-function assays revealed that BPNT1 acted as a novel oncogenic driver to promote TNBC cell proliferation, migration, invasion in vitro and to accelerate xenograft tumor growth and lung metastasis in mice. Mechanistically, BPNT1 recruited E3 ubiquitin ligase STUB1 (STIP1 homology and U-box containing protein 1) to induce proteasomal degradation of tumor suppressor protein LIMA1 (LIM domain and actin binding 1), thus promoting the epithelial-mesenchymal transition process and TNBC progression. Notably, re-expression of LIMA1 in BPNT1-overexpressing cells partially attenuated BPNT1-driven EMT and malignant phenotypes of TNBC cells. Furthermore, knockdown of BPNT1 enhanced the sensitivity of TNBC cells to the chemotherapeutic agent docetaxel. Collectively, these findings uncover a previously unknown role of the BPNT1-STUB1-LIMA1 axis in progression and docetaxel resistance in TNBC, and highlight BPNT1 as a potential therapeutic target for patients with TNBC.

> **中文摘要：**
> 三阴性乳腺癌（TNBC）是乳腺癌中最具侵袭性的亚型，缺乏有效的靶向疗法。我们中心对TNBC转录组和蛋白质组数据的整合分析显示，双磷酸核苷酸酶1（BPNT1）——一种肌醇单磷酸酶超家族成员，其在人类癌症中的功能和机制作用尚不明确——在TNBC中异常上调，且其高表达与患者不良预后相关。功能缺失和功能获得实验表明，BPNT1作为一种新型致癌驱动因子，在体外能促进TNBC细胞增殖、迁移和侵袭，在小鼠体内能加速异种移植瘤生长和肺转移。从机制上讲，BPNT1招募E3泛素连接酶STUB1（STIP1同源和U-box包含蛋白1），诱导肿瘤抑制蛋白LIMA1（LIM结构域和肌动蛋白结合蛋白1）发生蛋白酶体降解，从而促进上皮-间质转化过程和TNBC进展。值得注意的是，在BPNT1过表达的细胞中重新表达LIMA1，部分减弱了BPNT1驱动的EMT和TNBC细胞的恶性表型。此外，敲低BPNT1增强了TNBC细胞对化疗药物多西他赛的敏感性。总之，这些发现揭示了BPNT1-STUB1-LIMA1轴在TNBC进展和多西他赛耐药中先前未知的作用，并强调了BPNT1作为TNBC患者的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在探索BPNT1在TNBC中的功能及机制。通过整合多组学数据、体内外功能实验及机制研究，发现BPNT1通过招募STUB1泛素化降解抑癌蛋白LIMA1，驱动EMT和肿瘤进展，并介导化疗耐药。其创新性在于首次揭示了BPNT1-STUB1-LIMA1这一全新的促癌信号轴，为TNBC提供了潜在的治疗靶点。局限性在于，研究主要基于临床前模型，其临床转化价值及在更广泛样本中的预后关联性仍需进一步验证。

---

## 9. 靶向PLK1通过抑制JAK1/STAT3通路增强EGFR-TKIs的抗肿瘤疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41539998)
**期刊：** Cell death & disease
**PMID：** 41539998
**DOI：** 10.1038/s41419-025-08220-9

### 第一部分 原文与翻译

**英文原标题：** Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway.

> **英文摘要：**
> Despite the rapid development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in recent decades, resistance remains a significant challenge in managing advanced non-small cell lung cancer (NSCLC). Elucidating the mechanisms underlying EGFR-TKI resistance and developing novel strategies are therefore crucial. In this study, we investigated the role of polo-like kinase 1 (PLK1) in EGFR-mutant NSCLC and evaluated the therapeutic potential of combining EGFR-TKIs with PLK1 inhibitors. We demonstrated that high PLK1 expression correlates with STAT3 signaling activation and decreased survival probability in EGFR-mutant NSCLC patients. Subsequent studies revealed that PLK1 inhibitors effectively reversed the activation of STAT3 induced by EGFR-TKIs. When used in combination with EGFR-TKIs, they promoted cell apoptosis, inhibited cell proliferation in vitro, and induced tumor regression in animal models. Mechanistically, our data demonstrated that PLK1 regulated STAT3 activity through protein-protein interactions and JAK1-mediated phosphorylation, while STAT3 reciprocally regulated PLK1 transcription, establishing a positive feedback loop between these signaling molecules. This PLK1/STAT3 loop was further reinforced by FGFR1 upregulation and directly linked to EGFR-TKI resistance. Targeting this axis with combinatorial inhibitors exerted synergistic anti-tumor effects, suppressing proliferation and migration in osimertinib-resistant models. In conclusion, concurrent inhibition of EGFR and FGFR1/STAT3/PLK1 signaling pathways provides a promising therapeutic strategy for NSCLC patients with EGFR mutations, enhancing efficacy and overcoming resistance.

> **中文摘要：**
> 尽管近几十年来表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）发展迅速，但耐药性仍然是治疗晚期非小细胞肺癌（NSCLC）的重大挑战。因此，阐明EGFR-TKI耐药的机制并开发新策略至关重要。在本研究中，我们探讨了polo样激酶1（PLK1）在EGFR突变NSCLC中的作用，并评估了EGFR-TKIs与PLK1抑制剂联合治疗的治疗潜力。我们证明，高PLK1表达与STAT3信号激活相关，并降低了EGFR突变NSCLC患者的生存概率。后续研究表明，PLK1抑制剂能有效逆转EGFR-TKIs诱导的STAT3激活。当与EGFR-TKIs联合使用时，它们能促进细胞凋亡、抑制体外细胞增殖，并在动物模型中诱导肿瘤消退。从机制上讲，我们的数据表明，PLK1通过蛋白质-蛋白质相互作用和JAK1介导的磷酸化来调节STAT3活性，而STAT3则反过来调节PLK1的转录，从而在这些信号分子之间建立了一个正反馈环路。该PLK1/STAT3环路被FGFR1上调进一步强化，并与EGFR-TKI耐药直接相关。使用组合抑制剂靶向该轴产生了协同抗肿瘤效应，抑制了奥希替尼耐药模型的增殖和迁移。总之，同时抑制EGFR和FGFR1/STAT3/PLK1信号通路为EGFR突变的NSCLC患者提供了一种有前景的治疗策略，可增强疗效并克服耐药。

### 第二部分 AI 大师评价

本研究旨在探索克服EGFR-TKI耐药的新策略，聚焦于PLK1在EGFR突变NSCLC中的作用。通过临床数据分析、体外细胞实验和体内动物模型，研究发现PLK1与STAT3信号形成正反馈环路，并与FGFR1上调共同驱动耐药。其核心创新在于揭示了PLK1/STAT3/JAK1/FGFR1这一新的信号轴，并证明联合靶向EGFR和该轴具有协同抗肿瘤效果。然而，研究局限性在于主要基于临床前模型，其转化至临床的有效性和安全性仍需进一步验证，且对环路中具体蛋白相互作用的结构细节阐述有限。

---

## 10. PP2A激活靶向神经母细胞瘤中的MYCN。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41539997)
**期刊：** Cell death & disease
**PMID：** 41539997
**DOI：** 10.1038/s41419-025-08253-0

### 第一部分 原文与翻译

**英文原标题：** PP2A activation targets MYCN in neuroblastoma.

> **英文摘要：**
> Neuroblastoma (NBL) is the most common extracranial solid tumor of childhood, accounting for 7-10% of all children cancers, but leading to 15% of childhood cancer related deaths. Children with high-risk neuroblastoma (HR-NBL) lack effective treatments that achieve durable outcomes. While multiple factors stratify NBL patients into the high- risk category, MYCN amplification is a crucial determinant for that group. Thus far, efforts towards directly targeting MYCN have proven unsuccessful. Serine/threonine protein phosphatase 2 A (PP2A) functions as a tumor suppressor across cancers through its epigenetic effects, and its activity and tumor suppressor function are inhibited in NBL. We hypothesized that MYCN may be a target for PP2A, and that reactivation of PP2A may have a tumor suppressive effect on NBL. We employed studies to document the phenotypic, epigenetic, and in vivo effects of pharmacologic PP2A activation. Novel PP2A activators, ATUX-1215 or ATUX-5800, reduced MYCN mRNA abundance and MYCN phosphorylation and protein expression. PP2A activation decreased the acetylation of H3K27 (H3K27ac) as well as the enrichment of H3K27ac at the MYCN promoter. ATUX-1215 and ATUX-5800 treatment led to hypophosphorylation of RNA Pol II carboxy-terminal domain (CTD) and BRD4, transcriptional and epigenetic regulators respectively, coinciding with decreased MYCN expression and gene regulator acetylation. Tumor growth decreased in animals treated with ATUX-1215, and analysis of tumor specimens confirmed decreased MYCN expression. We conclude that pharmacologic PP2A reactivation may be a relevant therapeutic component in NBL treatment through its targeting of MYCN.

> **中文摘要：**
> 神经母细胞瘤（NBL）是儿童最常见的颅外实体瘤，占所有儿童癌症的7-10%，但导致了15%的儿童癌症相关死亡。高危神经母细胞瘤（HR-NBL）患儿缺乏能够实现持久疗效的有效治疗方法。虽然多种因素将NBL患者分层至高危类别，但MYCN扩增是该组患者的关键决定因素。迄今为止，直接靶向MYCN的努力已被证明是失败的。丝氨酸/苏氨酸蛋白磷酸酶2A（PP2A）通过其表观遗传效应在多种癌症中发挥肿瘤抑制作用，但其活性和抑瘤功能在NBL中被抑制。我们假设MYCN可能是PP2A的靶点，并且PP2A的再激活可能对NBL产生抑瘤作用。我们通过研究记录了药理性PP2A激活的表型、表观遗传和体内效应。新型PP2A激活剂ATUX-1215或ATUX-5800降低了MYCN mRNA丰度、MYCN磷酸化及蛋白表达。PP2A激活降低了H3K27的乙酰化（H3K27ac）以及H3K27ac在MYCN启动子区的富集。ATUX-1215和ATUX-5800处理导致RNA聚合酶II羧基末端结构域（CTD）和BRD4的低磷酸化，这两者分别是转录和表观遗传调控因子，这与MYCN表达和基因调控因子乙酰化的降低相一致。在用ATUX-1215治疗的动物中，肿瘤生长减缓，并且肿瘤标本分析证实了MYCN表达的降低。我们得出结论，药理性PP2A再激活通过靶向MYCN，可能成为NBL治疗中的一个相关治疗组成部分。

### 第二部分 AI 大师评价

本研究旨在探索通过药理性激活PP2A来靶向神经母细胞瘤关键致癌因子MYCN的治疗新策略。研究者采用新型小分子激活剂ATUX-1215/5800，通过体内外实验证实了PP2A激活能有效降低MYCN的转录、翻译及磷酸化水平，并揭示了其通过下调H3K27ac、RNA Pol II CTD及BRD4磷酸化等表观遗传与转录调控机制。其创新性在于绕过了直接靶向MYCN的困难，转而激活其上游抑癌磷酸酶PP2A，为高危神经母细胞瘤提供了新的治疗思路。然而，研究局限性在于临床前数据，其人体有效性与安全性尚待临床试验验证，且PP2A作为广泛调控的酶，其选择性激活的长期影响需进一步评估。

---

## 11. 十二指肠复合性节细胞神经瘤/神经瘤与神经内分泌肿瘤（CoGNET）：内分泌病理学图像探索肿瘤成分中生物标志物的表达模式。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41537937)
**期刊：** Endocrine pathology
**PMID：** 41537937
**DOI：** 10.1007/s12022-026-09901-7

### 第一部分 原文与翻译

**英文原标题：** Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor (CoGNET) of the Duodenum: An Image in Endocrine Pathology Exploring Patterns of Biomarker Expression in Tumor Elements.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文聚焦于一种罕见的十二指肠复合性肿瘤（CoGNET），其核心目的是通过病理学图像，深入探索肿瘤内不同成分（节细胞神经瘤/神经瘤与神经内分泌肿瘤）的生物标志物表达模式。研究采用基于图像的形态学与免疫组化分析相结合的方法，旨在揭示这种复合性肿瘤的生物学特性。其创新性在于对这类罕见肿瘤的分子表型进行了系统性描绘，为病理诊断和分类提供了新的见解。然而，由于摘要缺失，无法获知其具体的研究发现、样本量及潜在的临床相关性，这构成了当前信息的主要局限性。

---

## 12. Erdafitinib单药或联合Cetrelimab治疗伴有FGFR改变的转移性尿路上皮癌患者：II期NORSE研究的最终结果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538748)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41538748
**DOI：** 10.1200/JCO-25-00826

### 第一部分 原文与翻译

**英文原标题：** Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and  Alterations: Final Results From the Phase II NORSE Study.

> **英文摘要：**
> PURPOSE: First-line treatment options for cisplatin-ineligible patients with metastatic urothelial cancer (mUC) are limited. We conducted a phase II study of erdafitinib, alone or with cetrelimab, in -altered mUC. METHODS: Adults with mUC and select  alterations who are ineligible for cisplatin were randomly assigned 1:1 in a noncomparative design to once-daily erdafitinib 8 mg (with pharmacodynamically guided uptitration to 9 mg) or erdafitinib 8 mg plus intravenous cetrelimab 240 mg once every 2 weeks at cycles 1-4 and 480 mg once every 4 weeks thereafter. Primary end points were investigator-assessed confirmed overall response rate (ORR) and safety; secondary end points included duration of response (DOR), progression-free survival, and overall survival (OS). No statistical hypotheses were tested. RESULTS: At data cutoff, 87 patients were randomly assigned and treated (erdafitinib, n = 43; erdafitinib plus cetrelimab, n = 44). Of 64 patients with PD-L1 expression data, 56 (87.5%) had low levels of PD-L1 expression (combined positive score <10). Median survival follow-up was 14.2 months. Investigator-assessed confirmed ORR for erdafitinib was 44.2% (95% CI, 29.1 to 60.1) with one complete response (CR); median DOR and median OS were 9.7 months (95% CI, 4.6 to not estimable [NE]) and 16.2 months (95% CI, 8.3 to NE), respectively. Investigator-assessed confirmed ORR for erdafitinib plus cetrelimab was 54.5% (95% CI, 38.8 to 69.6), with six (13.6%) CRs; median DOR and median OS were 11.1 months (95% CI, 8.8 to NE) and 20.8 months (95% CI, 12.0 to NE), respectively. The most frequent treatment相关不良事件 (TRAEs) were hyperphosphatemia (83.7% and 68.2% in erdafitinib and erdafitinib plus cetrelimab groups, respectively), stomatitis (69.8% and 56.8%), and dry mouth (37.2% and 56.8%). Grade ≥3 TRAEs occurred in 46.5% and 45.5% of patients receiving erdafitinib and erdafitinib plus cetrelimab, respectively. CONCLUSION: First-line erdafitinib monotherapy and erdafitinib plus cetrelimab demonstrated antitumor activity and a manageable safety profile in cisplatin-ineligible patients with mUC.

> **中文摘要：**
> 目的：对于不适合顺铂治疗的转移性尿路上皮癌（mUC）患者，一线治疗选择有限。我们进行了一项II期研究，评估erdafitinib单药或联合cetrelimab在伴有FGFR改变的mUC患者中的疗效。方法：伴有特定FGFR改变且不适合顺铂治疗的mUC成人患者，按1:1以非比较性设计随机分配至每日一次erdafitinib 8 mg组（根据药效学指导可上调至9 mg）或erdafitinib 8 mg联合静脉注射cetrelimab组（第1-4周期每2周240 mg，此后每4周480 mg）。主要终点为研究者评估的确认客观缓解率（ORR）和安全性；次要终点包括缓解持续时间（DOR）、无进展生存期和总生存期（OS）。未进行统计假设检验。结果：截至数据截止时，共87例患者被随机分配并接受治疗（erdafitinib组，n = 43；erdafitinib联合cetrelimab组，n = 44）。在64例有PD-L1表达数据的患者中，56例（87.5%）PD-L1表达水平较低（综合阳性评分<10）。中位生存随访时间为14.2个月。研究者评估的erdafitinib组确认ORR为44.2%（95% CI，29.1至60.1），其中1例完全缓解（CR）；中位DOR和中位OS分别为9.7个月（95% CI，4.6至不可估计[NE]）和16.2个月（95% CI，8.3至NE）。研究者评估的erdafitinib联合cetrelimab组确认ORR为54.5%（95% CI，38.8至69.6），其中6例（13.6%）为CR；中位DOR和中位OS分别为11.1个月（95% CI，8.8至NE）和20.8个月（95% CI，12.0至NE）。最常见的治疗相关不良事件（TRAEs）为高磷血症（erdafitinib组和联合组分别为83.7%和68.2%）、口腔炎（69.8%和56.8%）和口干（37.2%和56.8%）。≥3级TRAEs在erdafitinib组和联合组中的发生率分别为46.5%和45.5%。结论：一线erdafitinib单药及erdafitinib联合cetrelimab在不适合顺铂治疗的mUC患者中显示出抗肿瘤活性和可控的安全性。

### 第二部分 AI 大师评价

本研究旨在探索不适合顺铂治疗的、伴有FGFR改变的转移性尿路上皮癌患者的一线治疗新策略。通过一项非比较性II期试验，评估了FGFR抑制剂erdafitinib单药及其联合PD-1抑制剂cetrelimab的疗效与安全性。核心发现是，联合治疗组在客观缓解率（54.5% vs 44.2%）和总生存期（中位20.8个月 vs 16.2个月）上均显示出优于单药治疗的趋势，且安全性可控。其创新性在于为这一特定人群提供了精准靶向联合免疫治疗的有效证据，但局限性在于样本量较小、非比较性设计，且研究人群主要为PD-L1低表达者，限制了结果在更广泛人群中的外推性。

---

## 13. 淋巴结阳性、激素受体阳性乳腺癌绝经前患者在5年辅助性促黄体激素释放激素激动剂治疗后延长内分泌治疗：一项队列研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538747)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41538747
**DOI：** 10.1200/JCO-25-01660

### 第一部分 原文与翻译

**英文原标题：** Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.

> **英文摘要：**
> PURPOSE: To evaluate the clinical benefit of extended endocrine therapy (eET) after 5 years of adjuvant treatment with luteinizing hormone-releasing hormone agonists (LHRHa) in premenopausal women with node-positive, hormone receptor-positive early breast cancer (eBC). METHODS: We conducted a cohort study analysis on two prospectively收集的数据集（Young Women's Breast Cancer Study 和 IEO Breast Cancer Cohort）。 Eligible patients were diagnosed with eBC at age ≤40 years (between 2005 and 2016), had node-positive, hormone receptor-positive disease, and remained premenopausal after 5 years of adjuvant LHRHa with no evidence of recurrence. The primary end point was invasive breast cancer-free survival (IBCFS), calculated from the sixth year after the initiation of adjuvant endocrine therapy (ET; study baseline), and adjusted through the propensity score (PS) weighting analysis. RESULTS: A total of 501 patients were included in the analysis: 287 received eET for a median duration of 3.7 years (IQR, 2.3-5.0), including 48% tamoxifen monotherapy and 52% LHRHa plus tamoxifen or aromatase inhibitor. After a median follow-up of 7.3 years from the study baseline, the PS weighted IBCFS rates at 5 years were 85% in the eET group and 78% in the non-eET group (hazard ratio [HR], 0.63 [95% CI, 0.44 to 0.89];  = .0135). The PS weighted distant recurrence-free survival rates at 5 years were 91% and 83% in the eET and non-eET group, respectively (cause-specific HR, 0.49 [95% CI, 0.31 to 0.79]). In both groups, bone fractures and major cardiovascular events were reported in 1% of patients. CONCLUSION: In this cohort study analysis, extending ET in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment was associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences.

> **中文摘要：**
> 目的：评估淋巴结阳性、激素受体阳性早期乳腺癌（eBC）绝经前女性在完成5年辅助性促黄体激素释放激素激动剂（LHRHa）治疗后，延长内分泌治疗（eET）的临床获益。方法：我们对两个前瞻性收集的数据集（Young Women's Breast Cancer Study 和 IEO Breast Cancer Cohort）进行了队列研究分析。符合条件的患者为年龄≤40岁（2005年至2016年间）诊断为eBC，患有淋巴结阳性、激素受体阳性疾病，并在完成5年辅助LHRHa治疗后仍处于绝经前状态且无复发证据。主要终点是无浸润性乳腺癌生存期（IBCFS），从辅助内分泌治疗（ET）开始后的第六年（研究基线）起算，并通过倾向评分（PS）加权分析进行调整。结果：共有501名患者被纳入分析：其中287人接受了eET，中位持续时间为3.7年（IQR，2.3-5.0），包括48%的他莫昔芬单药治疗和52%的LHRHa联合他莫昔芬或芳香化酶抑制剂。从研究基线起中位随访7.3年后，PS加权的5年IBCFS率在eET组为85%，在非eET组为78%（风险比[HR]，0.63 [95% CI，0.44至0.89]；P = .0135）。PS加权的5年无远处复发生存率在eET组和非eET组分别为91%和83%（病因特异性HR，0.49 [95% CI，0.31至0.79]）。两组中均有1%的患者报告了骨折和主要心血管事件。结论：在这项队列研究分析中，对于淋巴结阳性eBC的绝经前患者，在5年LHRHa治疗后延长ET，与浸润性和远处乳腺癌复发具有临床意义的减少相关。

### 第二部分 AI 大师评价

本研究聚焦于淋巴结阳性、激素受体阳性早期乳腺癌绝经前患者完成5年标准辅助内分泌治疗后延长治疗的关键临床问题。其创新性在于利用两个高质量前瞻性队列数据，专门针对年轻高危人群，采用倾向评分加权方法分析延长内分泌治疗的获益。核心发现表明，延长治疗能显著改善无浸润性乳腺癌生存和无远处复发生存，且未显著增加骨折和心血管事件风险。局限性在于其为观察性队列研究，可能存在未测量的混杂因素，且延长治疗的方案（单药或联合）存在异质性，需随机对照试验进一步验证。

---

## 14. 医疗保险处方药支付计划对诊断为癌症的医疗保险D部分受益人的潜在影响。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538746)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41538746
**DOI：** 10.1200/JCO-25-01788

### 第一部分 原文与翻译

**英文原标题：** Potential Impact of the Medicare Prescription Payment Plan for Medicare Part D Beneficiaries With a Cancer Diagnosis.

> **英文摘要：**
> PURPOSE: To address high out-of-pocket (OOP) medication costs among Medicare Part D beneficiaries, the 2022 Inflation Reduction Act introduced the Medicare Prescription Payment Plan (M3P), a voluntary program that allows beneficiaries to spread OOP costs over the calendar year. We examined M3P's potential impact among beneficiaries with cancer, who frequently incur substantial early-year Part D medication costs.
> 
> MATERIALS AND METHODS: We evaluated a 2022 5% random sample of Medicare beneficiaries with a cancer diagnosis and ≥1 fill for a cancer-indicated Part D medication. We estimated 2025-adjusted annual true OOP spending and median monthly beneficiary OOP payment obligations with and without M3P enrollment. Subgroup analyses were performed by demographics, nonadherence status in 2022, and Part D benefit phase.
> 
> RESULTS: Among 168,480 beneficiaries with cancer, most were diagnosed with breast (47.6%), dermatologic (17.6%), or prostate (13.3%) cancers. Overall, 46.7% were projected to reach catastrophic coverage in 2025, with 32.4% doing so in January. Breast (29.7%), prostate (21.20%), and hematologic (20.0%) cancers were most common among those reaching catastrophic coverage. Overall, 43.0% were nonadherent to cancer-indicated Part D medications, with 31.5% reaching catastrophic coverage in January 2025. M3P reduced beneficiary payment obligation variability, especially among those reaching the catastrophic phase in January (IQR, $1,798 US dollars [USD] no M3P  $118 USD M3P). Of those reaching catastrophic coverage with a cancer-indicated drug (58.6% overall), 89.2% did so in January.
> 
> CONCLUSION: Early-year entry into catastrophic coverage is common among beneficiaries with certain high-cost cancers. M3P may most effectively reduce financial burden when enrollment occurs before January. Targeted outreach from cancer care teams and Part D plans to nonadherent patients and those considering costly therapies could maximize program impact and improve treatment outcomes.

> **中文摘要：**
> 目的：为解决医疗保险D部分受益人自付（OOP）药物费用高昂的问题，2022年《通胀削减法案》引入了医疗保险处方药支付计划（M3P），这是一项允许受益人将全年OOP费用分摊支付的志愿计划。我们研究了M3P在癌症受益人中的潜在影响，这部分人群经常在年初就产生高昂的D部分药物费用。
> 
> 材料与方法：我们评估了2022年诊断为癌症且至少配过一次癌症适应症D部分药物的医疗保险受益人5%随机样本。我们估算了经2025年调整后的年度真实OOP支出，以及加入与不加入M3P情况下受益人每月OOP支付义务的中位数。按人口统计学特征、2022年非依从状态以及D部分福利阶段进行了亚组分析。
> 
> 结果：在168,480名癌症受益人当中，大多数被诊断为乳腺癌（47.6%）、皮肤癌（17.6%）或前列腺癌（13.3%）。总体而言，预计46.7%的受益人将在2025年达到灾难性保险阶段，其中32.4%在1月份达到。在达到灾难性保险阶段的受益人中，乳腺癌（29.7%）、前列腺癌（21.20%）和血液系统癌症（20.0%）最为常见。总体而言，43.0%的受益人对癌症适应症D部分药物存在非依从性，其中31.5%将在2025年1月达到灾难性保险阶段。M3P降低了受益人支付义务的变异性，尤其是在1月份达到灾难性阶段的受益人中（四分位距，未加入M3P为1,798美元，加入M3P为118美元）。在使用癌症适应症药物达到灾难性保险阶段的受益人中（总体占58.6%），89.2%是在1月份达到的。
> 
> 结论：年初即进入灾难性保险阶段在患有某些高成本癌症的受益人中很常见。若在1月前加入，M3P可能最有效地减轻经济负担。癌症护理团队和D部分计划针对非依从患者及考虑昂贵疗法的患者进行有针对性的外展，可以最大化该计划的影响并改善治疗结果。

### 第二部分 AI 大师评价

本研究聚焦于2022年《通胀削减法案》引入的医疗保险处方药支付计划（M3P）对癌症患者的潜在影响，具有明确的政策评估价值。其创新性在于利用真实世界数据，前瞻性模拟了M3P在2025年的实施效果，并特别关注了高成本癌症患者年初即进入“灾难性保险阶段”这一关键财务节点。研究发现，M3P能显著平滑患者月度支付波动，尤其对年初即面临高额药费的患者效果显著。局限性在于，分析基于2022年数据的预测模型，实际效果可能受未来药价、参保行为及政策细则变化的影响；此外，研究主要关注财务指标，对M3P如何具体影响治疗依从性和临床结局的机制探讨尚不深入。

---

## 15. PU.1激活的基因组区域定义了以免疫失调和疾病进展为特征的低危MDS亚群。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538708)
**期刊：** Blood
**PMID：** 41538708
**DOI：** 10.1182/blood.2025030760

### 第一部分 原文与翻译

**英文原标题：** PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.

> **英文摘要：**
> Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms with an increased risk of progression to secondary acute myeloid leukemia (sAML). This study investigates the genomic correlates of disease progression in MDS by profiling active genomic regulatory regions and their transcriptional impact through H3K27ac ChIP-seq and RNA-seq analysis on CD34+ bone marrow progenitors cells isolated from a prospective cohort of 86 and 357 patients, respectively. Our analysis revealed distinct patterns of genomic region activation and transcriptional regulation across different disease stages (low-risk MDS, high-risk MDS and sAML). Unexpectedly, unsupervised clustering revealed a subset of low-risk MDS patients displaying regulatory and transcriptional profiles similar to those of high-risk MDS and sAML, highlighting early molecular events that may predispose patients to disease progression. This subset is characterized by PU.1 genomic occupancy in regions linked to immune and inflammatory responses, increased T-cell and NK activation, and a higher frequency of SRSF2 mutations. Clinically, patients in this group exhibit greater susceptibility to infections and cardiovascular events, along with an elevated risk of disease progression, resulting in a significantly reduced overall survival. Functional studies demonstrate that PU.1 inhibition suppresses MDS cell proliferation and clonogenicity, as impaired PU.1 binding inhibits the activation of key transcriptional programs involved in disease advancement. Collectively, these findings identify epigenetic factors that predispose low-risk MDS patients to progression into high-risk MDS and, ultimately, sAML.

> **中文摘要：**
> 骨髓增生异常综合征（MDS）是一类异质性的髓系肿瘤，其进展为继发性急性髓系白血病（sAML）的风险增加。本研究旨在通过分析基因组活性调控区域及其转录影响，探究MDS疾病进展的基因组相关性。研究分别对来自前瞻性队列的86名和357名患者的CD34+骨髓祖细胞进行了H3K27ac ChIP-seq和RNA-seq分析。我们的分析揭示了不同疾病阶段（低危MDS、高危MDS和sAML）之间基因组区域激活和转录调控的独特模式。出乎意料的是，无监督聚类分析揭示了一个低危MDS患者亚群，其调控和转录谱与高危MDS和sAML相似，这突显了可能使患者易发生疾病进展的早期分子事件。该亚群的特征是PU.1在免疫和炎症反应相关基因组区域的占据、T细胞和NK细胞活化增强以及SRSF2突变频率更高。临床上，该组患者表现出对感染和心血管事件更高的易感性，以及疾病进展风险升高，导致总生存期显著缩短。功能研究表明，抑制PU.1可抑制MDS细胞的增殖和克隆形成能力，因为受损的PU.1结合会抑制参与疾病进展的关键转录程序的激活。总之，这些发现确定了使低危MDS患者易于进展为高危MDS并最终发展为sAML的表观遗传因素。

### 第二部分 AI 大师评价

本研究通过整合H3K27ac ChIP-seq与RNA-seq多组学技术，前瞻性地描绘了MDS疾病进展的调控图谱。其核心创新在于，在传统低危MDS患者中识别出一个具有高危分子特征和不良临床预后的新亚群，该亚群由PU.1驱动的免疫炎症通路异常所定义。这不仅为MDS的风险分层提供了新的表观遗传学标志，还提示PU.1可能是该高危亚群的潜在治疗靶点。然而，研究结论主要基于相关性分析，PU.1在该亚群疾病进展中的直接因果作用及靶向干预的临床转化潜力，仍需后续功能实验和前瞻性临床试验进一步验证。

---

## 16. 具有增强双光子吸收截面的近红外共晶纳米荧光团。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538468)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41538468
**DOI：** 10.1002/advs.202523319

### 第一部分 原文与翻译

**英文原标题：** Near-Infrared Cocrystal Nanofluorophore with Enhanced Two-Photon Absorption Cross Sections.

> **英文摘要：**
> The growing demand for organic nanoprobes that combine broadband two-photon absorption (TPA) with near-infrared (NIR) optical excitation continues to drive advancements in biological imaging and advanced photonics. However, the design and preparation of such nanoprobe materials remain a significant challenge. Here, we employ co-crystallization strategy to fabricate a TPA crystal material, BP4TC (donor BP4VA, acceptor TCNB), exhibiting deep red fluorescence. Nanoprecipitation with an amphiphilic surfactant yields water-dispersible BP4TC nanoparticles (BP4TC-NPs, ≈50 nm), which are subsequently used for open-aperture Z-scan measurements. This marks the first experimental determination of the TPA cross-section for a molecular multicomponent solid. Prominent reverse-saturable and saturable absorption characteristics span 700-1000 nm, with corresponding TPA cross-sections decreasing monotonically with increasing wavelength. First-principles calculations demonstrate that BP4TC exhibits a stronger intermolecular charge transfer capacity, verifying its enhanced TPA ability. The TPA cross-section of BP4TC was further computed using the TDDFT approach, and the result indicates that BP4TC is a potent two-photon absorber. Under 900 nm excitation, BP4TC-NPs produce bright, low-background fluorescence in A549 cells (human lung cancer cells), exhibiting negligible cytotoxicity. Notably, by combining broadband NIR-I TPA with favorable biological properties, these cocrystal materials establish a multifunctional platform for biological multiphoton imaging and NIR photonics, while providing an experimentally validated blueprint for advanced nonlinear optical nanomaterials.

> **中文摘要：**
> 对兼具宽带双光子吸收（TPA）与近红外（NIR）光学激发的有机纳米探针的需求日益增长，持续推动着生物成像和先进光子学的发展。然而，此类纳米探针材料的设计与制备仍然是一个重大挑战。在此，我们采用共结晶策略制备了一种TPA晶体材料BP4TC（给体BP4VA，受体TCNB），其显示出深红色荧光。通过使用两亲性表面活性剂进行纳米沉淀，得到了水分散性的BP4TC纳米颗粒（BP4TC-NPs，≈50 nm），并随后用于开孔Z扫描测量。这标志着首次对分子多组分固体的TPA截面进行了实验测定。在700-1000 nm范围内表现出显著的反饱和与饱和吸收特性，相应的TPA截面随波长增加单调递减。第一性原理计算表明，BP4TC表现出更强的分子间电荷转移能力，验证了其增强的TPA能力。使用TDDFT方法进一步计算了BP4TC的TPA截面，结果表明BP4TC是一种有效的双光子吸收体。在900 nm激发下，BP4TC-NPs在A549细胞（人肺癌细胞）中产生明亮、低背景的荧光，且表现出可忽略的细胞毒性。值得注意的是，通过将宽带NIR-I TPA与良好的生物学特性相结合，这些共晶材料为生物多光子成像和NIR光子学建立了一个多功能平台，同时为先进的非线性光学纳米材料提供了一个经过实验验证的蓝图。

### 第二部分 AI 大师评价

本研究旨在应对兼具宽带双光子吸收与近红外激发特性的有机纳米探针的设计挑战。其核心创新在于采用共结晶策略，首次成功制备并实验测定了分子多组分固体（BP4TC共晶）的双光子吸收截面，填补了该领域的实验空白。研究通过理论计算验证了材料性能增强的机制，并展示了其在细胞成像中低毒、高亮度的应用潜力，为非线性光学纳米材料提供了一个从设计、表征到生物应用验证的完整范例。然而，摘要未提及该纳米颗粒在复杂生物体内的长期稳定性、代谢途径及更深度的活体成像应用效果，这些是未来转化研究需要关注的方向。

---

## 17. 核苷酸代谢重编程驱动肥胖中NLRP3炎症小体过度活化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538457)
**期刊：** Science (New York, N.Y.)
**PMID：** 41538457
**DOI：** 10.1126/science.adq9006

### 第一部分 原文与翻译

**英文原标题：** Nucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesity.

> **英文摘要：**
> Obesity is a major disease risk factor due to obesity-associated hyperinflammation. We found that obesity induced Nod-like receptor pyrin domain-containing 3 (NLRP3) inflammasome hyperactivation and excessive interleukin (IL)-1β production in macrophages by disrupting SAM and HD domain-containing protein 1 (SAMHD1), a deoxynucleoside triphosphate (dNTP) hydrolase crucial for nucleotide balance. This caused aberrant accumulation of dNTPs, which can be transported into mitochondria, and initiated mitochondrial DNA (mtDNA) neosynthesis, which increased the presence of oxidized mtDNA and triggered NLRP3 hyperactivation. Deletion of SAMHD1 promoted NLRP3 hyperactivation in cells isolated from zebrafish, mice, and humans. SAMHD1-deficient mice showed elevated circulating IL-1β, insulin resistance, and metabolic dysfunction-associated steatohepatitis. Blocking dNTP mitochondrial transport prevented NLRP3 hyperactivation in macrophages from obese patients and SAMHD1-deficient mice. Our study revealed that obesity by inhibiting SAMHD1 rewired macrophage nucleotide metabolism, thereby triggering NLRP3 inflammasome hyperactivation to drive disease progression.

> **中文摘要：**
> 肥胖是主要的疾病风险因素，这归因于肥胖相关的过度炎症。我们发现，肥胖通过破坏SAM和HD结构域蛋白1（SAMHD1）——一种对维持核苷酸平衡至关重要的脱氧核苷三磷酸（dNTP）水解酶——诱导了巨噬细胞中Nod样受体热蛋白结构域相关蛋白3（NLRP3）炎症小体的过度活化和白细胞介素（IL）-1β的过量产生。这导致了dNTP的异常积累，这些dNTP可以被转运到线粒体中，并启动线粒体DNA（mtDNA）的从头合成，从而增加了氧化mtDNA的存在并触发了NLRP3的过度活化。在斑马鱼、小鼠和人类分离的细胞中，敲除SAMHD1促进了NLRP3的过度活化。SAMHD1缺陷小鼠表现出循环IL-1β水平升高、胰岛素抵抗和代谢功能障碍相关脂肪性肝炎。阻断dNTP的线粒体转运可防止来自肥胖患者和SAMHD1缺陷小鼠的巨噬细胞中NLRP3的过度活化。我们的研究揭示，肥胖通过抑制SAMHD1重编程了巨噬细胞的核苷酸代谢，从而触发NLRP3炎症小体过度活化以驱动疾病进展。

### 第二部分 AI 大师评价

本研究旨在揭示肥胖相关过度炎症的代谢机制，核心目的是阐明核苷酸代谢如何驱动NLRP3炎症小体过度活化。研究采用多物种（斑马鱼、小鼠、人）细胞与动物模型，结合基因敲除和代谢通路干预（阻断线粒体dNTP转运）等方法。研究发现肥胖通过抑制SAMHD1导致dNTP积累，进而通过线粒体mtDNA合成与氧化触发NLRP3过度活化，这为肥胖相关代谢疾病提供了新的机制解释。其创新性在于将核苷酸代谢、线粒体功能与固有免疫激活联系起来，但研究主要聚焦于巨噬细胞，其他细胞类型的作用及该通路在更广泛肥胖并发症中的普适性有待进一步探索。

---

## 18. 消融（某基因）与米色脂肪特性导致血管重塑和血压升高。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538429)
**期刊：** Science (New York, N.Y.)
**PMID：** 41538429
**DOI：** 10.1126/science.ady8644

### 第一部分 原文与翻译

**英文原标题：** Ablation of  and beige fat identity causes vascular remodeling and elevated blood pressure.

> **英文摘要：**
> Excess adiposity is a major risk factor for hypertension and heart disease. Brown fat is associated with protection from cardiovascular pathology, but whether this relationship is causal remains unknown. In this work, we investigate the role of mouse beige fat, as a model of human inducible brown fat, in adipocyte-vascular cross-talk. Using adipocyte-specific  knockout mice with a loss of beige adipocyte identity, we discovered marked remodeling of perivascular adipose tissue, increased vascular reactivity, and elevated blood pressure. We show that the circulating enzyme QSOX1 is derepressed in -deficient adipocytes, and deletion of  in  conditional knockout mice prevented vascular fibrosis and normalized vascular reactivity. These results demonstrate a key role for beige adipocytes in blood pressure regulation and identify QSOX1 as an important mediator of adipocyte-vascular cross-talk.

> **中文摘要：**
> 脂肪组织过多是高血压和心脏病的主要风险因素。棕色脂肪与预防心血管病理相关，但这种关系是否具有因果性尚不清楚。在本研究中，我们以小鼠米色脂肪作为人类可诱导棕色脂肪的模型，探究其在脂肪细胞-血管交互对话中的作用。利用特异性敲除脂肪细胞中（某基因）并丧失米色脂肪细胞特性的小鼠，我们发现了血管周围脂肪组织的显著重塑、血管反应性增加以及血压升高。我们证明，循环酶QSOX1在（某基因）缺陷的脂肪细胞中被解除抑制，而在（某基因）条件性敲除小鼠中删除（另一基因）可预防血管纤维化并使血管反应性恢复正常。这些结果证明了米色脂肪细胞在血压调节中的关键作用，并确定QSOX1是脂肪细胞-血管交互对话的重要介质。

### 第二部分 AI 大师评价

本研究旨在探究米色脂肪细胞在血压调节中的因果性作用及机制。研究者采用脂肪细胞特异性基因敲除小鼠模型，通过表型分析发现米色脂肪特性丧失会导致血管重塑和高血压。其核心创新在于首次将循环酶QSOX1确定为介导脂肪-血管对话的关键分子，并提供了基因挽救实验的证据。然而，研究主要基于小鼠模型，其结论在人类中的普适性及QSOX1的具体作用通路仍需进一步验证。

---

## 19. 磁共振成像揭示脑膜淋巴管损伤在肺腺癌脑转移进展中的作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538419)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41538419
**DOI：** 10.1002/advs.202516988

### 第一部分 原文与翻译

**英文原标题：** Magnetic Resonance Imaging Reveals Meningeal Lymphatic Impairment in Lung Adenocarcinoma Brain Metastasis Progression.

> **英文摘要：**
> Meningeal lymphatic vessels (mLVs) contribute to brain immune surveillance; however, their structural and functional alterations in brain metastasis remain incompletely defined. Here, we optimized a magnetic resonance imaging protocol to quantitatively analyze mLV structure and drainage function. Using murine lung adenocarcinoma brain metastasis models and clinical imaging data, we reveal significant mLV disruption surrounding the superior sagittal sinus (SSS), which results in impaired drainage to deep cervical lymph nodes (dCLNs). Among ten cervical lymph-node levels assessed clinically, level IIA lymph nodes most accurately reflect mLV drainage efficiency. Functionally, mLV ablation compromised intrathecal chemotherapy efficacy in mice, while clinically, greater mLV structural and functional impairment correlates with disease progression in lung adenocarcinoma brain metastasis. Collectively, our findings demonstrate that lung adenocarcinoma brain metastases disrupt SSS-adjacent mLVs (mLVs-SSS), which potentially facilitates metastatic progression through compromised immune surveillance.

> **中文摘要：**
> 脑膜淋巴管（mLVs）参与大脑免疫监视；然而，其在脑转移中的结构和功能改变仍未完全阐明。本研究优化了一种磁共振成像方案，以定量分析脑膜淋巴管的结构和引流功能。通过使用小鼠肺腺癌脑转移模型和临床影像数据，我们揭示了上矢状窦（SSS）周围显著的脑膜淋巴管破坏，这导致向深部颈淋巴结（dCLNs）的引流功能受损。在临床评估的十个颈淋巴结分区中，IIA区淋巴结最能准确反映脑膜淋巴管的引流效率。功能上，在小鼠模型中，脑膜淋巴管消融损害了鞘内化疗的疗效；而在临床上，更严重的脑膜淋巴管结构和功能损伤与肺腺癌脑转移的疾病进展相关。总之，我们的研究结果表明，肺腺癌脑转移破坏了上矢状窦邻近的脑膜淋巴管，这可能通过损害免疫监视而促进转移进展。

### 第二部分 AI 大师评价

本研究旨在阐明脑膜淋巴管在肺腺癌脑转移中的变化及其功能意义。研究通过优化MRI方案，结合小鼠模型与临床数据，定量评估了脑膜淋巴管的结构与引流功能。核心发现是脑转移灶破坏了上矢状窦旁的脑膜淋巴管，导致引流功能受损，且这种损伤与疾病进展及鞘内化疗疗效降低相关。创新点在于建立了无创定量评估脑膜淋巴管功能的影像学方法，并明确了IIA区淋巴结作为关键评估指标，为理解脑转移的免疫逃逸机制和潜在治疗靶点提供了新视角；局限性在于主要揭示了相关性，其确切的因果机制及作为治疗靶点的可行性仍需进一步研究。

---

## 20. 一种用于哺乳动物细胞内转录组存储的基因编码装置。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41538410)
**期刊：** Science (New York, N.Y.)
**PMID：** 41538410
**DOI：** 10.1126/science.adz9353

### 第一部分 原文与翻译

**英文原标题：** A genetically encoded device for transcriptome storage in mammalian cells.

> **英文摘要：**
> Understanding how cells make decisions over time requires the ability to link past molecular states to future phenotypic outcomes. We present TimeVault, a genetically encoded system that records and stores transcriptomes within living mammalian cells for future readout. TimeVault leverages engineered vault particles that capture mRNA through poly(A) binding protein. We demonstrate that the transcriptome stored by TimeVaults is stable in living cells for over 7 days. TimeVault enables high-fidelity transcriptome-wide recording with minimal cellular perturbation, capturing transient stress responses and revealing gene expression changes underlying drug-naive persister states in lung cancer cells that evade EGFR inhibition. By linking past and present cellular states, TimeVault provides a powerful tool for decoding how cells respond to stress, make fate decisions, and resist therapy.

> **中文摘要：**
> 理解细胞如何随时间做出决策，需要具备将过去的分子状态与未来的表型结果联系起来的能力。我们提出了TimeVault，这是一种基因编码系统，可在活体哺乳动物细胞内记录并存储转录组，以供未来读取。TimeVault利用经过工程改造的穹窿体颗粒，通过poly(A)结合蛋白捕获mRNA。我们证明，TimeVault存储的转录组在活细胞内可稳定存在超过7天。TimeVault能够以最小的细胞扰动实现高保真的全转录组记录，捕获瞬时的应激反应，并揭示肺癌细胞中逃避EGFR抑制的、未经药物处理的持久态所依赖的基因表达变化。通过连接过去和现在的细胞状态，TimeVault为解码细胞如何响应应激、做出命运决定以及抵抗治疗提供了一个强大的工具。

### 第二部分 AI 大师评价

本研究旨在开发一种能够记录和存储活细胞内转录组历史信息的工具，以解析细胞动态决策过程。其核心方法是通过基因工程改造的穹窿体颗粒捕获并稳定存储mRNA，实现了长达一周以上的细胞内转录组记录。研究发现，该系统能高保真地捕获瞬时应激反应，并揭示了肺癌细胞对EGFR抑制剂产生初始耐受的基因表达基础。其创新性在于首次实现了活细胞内转录组信息的长期、原位“存档”，为研究细胞动态过程提供了革命性工具；局限性可能在于该系统的捕获效率、对特定mRNA的偏好性以及对细胞生理的潜在长期影响仍需进一步评估。

---

## 21. 早期小鼠胚胎中依赖H3K27me3的印记与转录调控需要EZHIP介导的对PRC2活性的限制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535302)
**期刊：** Nature communications
**PMID：** 41535302
**DOI：** 10.1038/s41467-026-68467-4

### 第一部分 原文与翻译

**英文原标题：** H3K27me3-dependent imprinting and transcriptional regulation in early mouse embryos requires EZHIP-mediated restriction of PRC2 activity.

> **英文摘要：**
> Zygotes inherit parental genomes with distinct chromatin structures. In eutherian mammals, this asymmetry is considered crucial for embryonic development, notably because it enables genomic imprinting. Besides the well-established role of DNA methylation in this process, a transient form of imprinting in mice has been shown to rely instead on H3K27me3. Here, we show that maternal deletion of Ezhip, encoding a negative regulator of PRC2, initially increases the asymmetric distribution of H3K27me3 among the parental genomes at the zygotic stage but subsequently impairs H3K27me3-dependent imprinting and mitigates X-chromosome inactivation in pre-implantation embryos. We show that EZHIP protein, translated from the maternal mRNA pool, is present during the first cell divisions post-fertilization and limits PRC2 enzymatic activity. In its absence, the H3K27me3 landscape is both expanded and flattened, and the asymmetry between the two parental genomes is lost. Our study reveals the deleterious consequences on early embryonic development of unleashing PRC2 activity.

> **中文摘要：**
> 合子继承了具有不同染色质结构的亲本基因组。在真兽类哺乳动物中，这种不对称性被认为对胚胎发育至关重要，特别是因为它能够实现基因组印记。除了DNA甲基化在这一过程中已确立的作用外，小鼠中一种短暂形式的印记已被证明依赖于H3K27me3。本研究中，我们发现母源缺失编码PRC2负调控因子的Ezhip基因，最初会增加合子阶段H3K27me3在亲本基因组间的不对称分布，但随后会损害依赖H3K27me3的印记并减弱植入前胚胎中的X染色体失活。我们证明，由母源mRNA池翻译的EZHIP蛋白存在于受精后的最初几次细胞分裂过程中，并限制PRC2的酶活性。在其缺失的情况下，H3K27me3的分布模式既被扩展也被扁平化，两个亲本基因组之间的不对称性随之丧失。我们的研究揭示了释放PRC2活性对早期胚胎发育的有害后果。

### 第二部分 AI 大师评价

本研究旨在阐明早期胚胎发育中，母源EZHIP蛋白通过限制PRC2活性来调控H3K27me3依赖的印记与转录的分子机制。研究者采用母源基因敲除模型，结合表观遗传学分析，发现EZHIP的缺失虽然短暂增强了H3K27me3的不对称性，但最终破坏了其依赖的印记和X染色体失活，导致表观景观扁平化。其创新性在于揭示了EZHIP在合子基因组激活后早期细胞分裂中的关键调控作用，为理解母源表观遗传信息传递提供了新视角。局限性在于研究主要基于小鼠模型，其结论在人类或其他哺乳动物中的普适性有待验证，且对下游具体靶基因和发育缺陷的长期影响探讨尚不深入。

---

## 22. 异常VEGFR2通过细胞外基质重塑支持肿瘤生长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535257)
**期刊：** Cell death & disease
**PMID：** 41535257
**DOI：** 10.1038/s41419-025-08404-3

### 第一部分 原文与翻译

**英文原标题：** Aberrant VEGFR2 supports tumor growth by extracellular matrix remodeling.

> **英文摘要：**
> The extracellular matrix shapes tumor architecture, cell behavior and therapy response. Here, we identify aberrant activation of the receptor tyrosine kinase VEGFR2 as a driver of tumor-promoting ECM remodeling in melanoma and ovarian cancer. ECM alterations in terms of composition and organization were observed in Sk-Mel-31 melanoma xenografts expressing the oncogenic VEGFR2 and in ovarian tumors with VEGFR2 hyperactivation. Down-modulation of VEGFR2 normalized ECM architecture. Decellularized ECM from VEGFR2 melanoma cells directly modified the behavior of VEGFR2 tumor cells, increasing monolayer fluidity and mitochondrial activation. Transcriptomic profiling revealed a dysregulation of genes involved in ECM structure and remodeling, mediated by the PI3K-AKT and ERK pathways. Pharmacological inhibition of VEGFR2 with tyrosine kinase inhibitors, such as lenvatinib, partially reverted ECM alterations in vitro and in vivo, reducing matrix deposition and modifying its organization. These data identify VEGFR2 as a regulator of tumor ECM dynamics and suggest that its inhibition may restore ECM organization, offering a therapeutic strategy to reprogram the tumor microenvironment and limit cancer progression.

> **中文摘要：**
> 细胞外基质塑造了肿瘤的结构、细胞行为和治疗反应。在此，我们确定受体酪氨酸激酶VEGFR2的异常激活是黑色素瘤和卵巢癌中促肿瘤ECM重塑的驱动因素。在表达致癌性VEGFR2的Sk-Mel-31黑色素瘤异种移植物以及VEGFR2过度激活的卵巢肿瘤中，观察到了ECM在组成和组织结构方面的改变。下调VEGFR2可使ECM结构正常化。来自VEGFR2黑色素瘤细胞的脱细胞ECM直接改变了VEGFR2肿瘤细胞的行为，增加了单层流动性和线粒体活化。转录组分析揭示了由PI3K-AKT和ERK通路介导的、参与ECM结构和重塑的基因失调。使用酪氨酸激酶抑制剂（如乐伐替尼）对VEGFR2进行药理学抑制，在体外和体内部分逆转了ECM的改变，减少了基质沉积并改变了其组织结构。这些数据将VEGFR2确定为肿瘤ECM动力学的调节因子，并表明抑制VEGFR2可能恢复ECM的组织结构，为重新编程肿瘤微环境和限制癌症进展提供了一种治疗策略。

### 第二部分 AI 大师评价

本研究旨在探究异常激活的VEGFR2在肿瘤细胞外基质重塑中的作用及其机制。研究通过黑色素瘤和卵巢癌模型，结合体内外实验、转录组学分析和药物干预，发现VEGFR2通过PI3K-AKT和ERK通路驱动促肿瘤的ECM重塑，而抑制VEGFR2可部分逆转这些改变。其创新性在于将VEGFR2的功能从传统的血管生成扩展到直接调控肿瘤基质，为通过靶向基质重塑来改善肿瘤微环境提供了新的治疗视角。局限性在于主要基于临床前模型，且药物干预仅部分逆转ECM改变，提示可能存在其他补偿机制。

---

## 23. 全球视角下的无烟烟草与口腔癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41534101)
**期刊：** The New England journal of medicine
**PMID：** 41534101
**DOI：** 10.1056/NEJMp2500631

### 第一部分 原文与翻译

**英文原标题：** Smokeless Tobacco and Oral Cancer in Global Perspective.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文旨在从全球视角探讨无烟烟草与口腔癌之间的关联。鉴于摘要不可用，推测其可能采用流行病学综述或荟萃分析的方法，整合不同地区的研究数据。其核心发现可能在于揭示无烟烟草在全球范围内对口腔癌负担的具体影响，并强调公共卫生干预的必要性。文章的创新性在于其宏观的全球视野，但缺乏摘要也限制了对其具体方法、数据和结论局限性的了解。

---

## 24. 在抗NMDAR脑炎主动免疫模型中，对自身抗体结合的NMDA受体进行冷冻电镜研究揭示了抗原热点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41533802)
**期刊：** Science advances
**PMID：** 41533802
**DOI：** 10.1126/sciadv.aeb4249

### 第一部分 原文与翻译

**英文原标题：** Cryo-EM of autoantibody-bound NMDA receptors reveals antigenic hotspots in an active immunization model of anti-NMDAR encephalitis.

> **英文摘要：**
> Autoantibodies targeting synaptic membrane proteins are associated with autoimmune encephalitis manifested by seizures, psychosis, and memory dysfunction. Anti--methyl-d-aspartate receptor (NMDAR) encephalitis, a prototype of these autoimmune synaptic disorders, is unexpectedly common. Unfortunately, how the native repertoire of anti-NMDAR autoantibodies recognizes NMDARs and the precise locations of antigenic epitopes remain poorly understood. Here, we used an active immunization model that closely mimics the human disease to immunize adult mice with intact GluN1/GluN2A receptors, resulting in fulminant autoimmune encephalitis. Serum was collected at 6 weeks postimmunization for single-particle cryo-electron microscopy of GluN1/GluN2A receptors complexed with purified polyclonal anti-NMDAR autoantibody fragments. Native autoantibodies recognized two distinct binding sites on the GluN1 amino-terminal domain, which we confirmed using monoclonal antibodies bound to native NMDARs purified from mouse brain. Structural analysis of autoantibody-bound NMDAR complexes identified antigenic hotspots within the GluN1 amino-terminal domain. These hotspots provide potential targets for therapeutic intervention.

> **中文摘要：**
> 靶向突触膜蛋白的自身抗体与表现为癫痫发作、精神症状和记忆功能障碍的自身免疫性脑炎相关。抗N-甲基-D-天冬氨酸受体（NMDAR）脑炎是这类自身免疫性突触疾病的原型，其发病率出乎意料地高。然而，天然的抗NMDAR自身抗体如何识别NMDAR，以及抗原表位的精确定位仍然知之甚少。在此，我们使用一种能密切模拟人类疾病的主动免疫模型，用完整的GluN1/GluN2A受体免疫成年小鼠，引发了暴发性自身免疫性脑炎。我们在免疫后6周收集血清，用于对与纯化的多克隆抗NMDAR自身抗体片段复合的GluN1/GluN2A受体进行单颗粒冷冻电镜分析。天然自身抗体识别了GluN1氨基末端结构域上的两个不同的结合位点，我们使用与从小鼠大脑中纯化的天然NMDAR结合的单克隆抗体证实了这一点。对自身抗体结合的NMDAR复合物的结构分析确定了GluN1氨基末端结构域内的抗原热点。这些热点为治疗干预提供了潜在靶点。

### 第二部分 AI 大师评价

本研究旨在阐明抗NMDAR脑炎中自身抗体识别NMDA受体的分子机制。研究者创新性地采用主动免疫小鼠模型，结合单颗粒冷冻电镜技术，首次在近生理状态下解析了多克隆自身抗体片段与天然NMDAR的复合物结构。核心发现是揭示了GluN1氨基末端结构域上两个不同的自身抗体结合位点，即“抗原热点”，这为理解疾病病理和开发靶向疗法提供了关键结构基础。然而，研究主要聚焦于GluN1/GluN2A亚型，且模型产生的抗体谱与患者天然抗体谱的完全一致性仍需进一步验证。

---

## 25. 一个转座酶衍生基因对人类大脑发育至关重要。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41533792)
**期刊：** Science advances
**PMID：** 41533792
**DOI：** 10.1126/sciadv.adv7530

### 第一部分 原文与翻译

**英文原标题：** A transposase-derived gene required for human brain development.

> **英文摘要：**
> Vertebrate brain development is associated with prominent neuronal cell death and DNA breaks, but their causes and functions are not well understood. DNA transposable elements could contribute to somatic genome rearrangements; however, their contributions to brain development are largely unknown. PiggyBac transposable element derived 5 (PGBD5) is an evolutionarily conserved vertebrate DNA transposase-derived gene with DNA remodeling activities in human cells. Here, we show that PGBD5 contributes to normal brain development in mice and humans, and its deficiency causes disorder of intellectual disability, movement disorders, and epilepsy. In mice, Pgbd5 is required for the developmental induction of postmitotic DNA breaks and recurrent somatic brain genome rearrangements. In the cerebral cortex, loss of Pgbd5 leads to aberrant neuronal gene expression, including of specific types of glutamatergic neurons, which partly explains the features of PGBD5 deficiency in humans. Thus, PGBD5 is a transposase-derived gene required for brain development in mammals.

> **中文摘要：**
> 脊椎动物大脑发育伴随着显著的神经元细胞死亡和DNA断裂，但其原因和功能尚不完全清楚。DNA转座元件可能导致体细胞基因组重排；然而，它们对大脑发育的贡献在很大程度上是未知的。PiggyBac转座元件衍生5（PGBD5）是一个在进化上保守的脊椎动物DNA转座酶衍生基因，在人类细胞中具有DNA重塑活性。本研究显示，PGBD5对小鼠和人类的正常大脑发育至关重要，其缺陷会导致智力障碍、运动障碍和癫痫等疾病。在小鼠中，Pgbd5是发育过程中诱导有丝分裂后DNA断裂和复发性体细胞大脑基因组重排所必需的。在大脑皮层中，Pgbd5的缺失会导致神经元基因表达异常，包括特定类型的谷氨酸能神经元，这部分解释了人类PGBD5缺陷的特征。因此，PGBD5是哺乳动物大脑发育所必需的一个转座酶衍生基因。

### 第二部分 AI 大师评价

本研究核心目的是阐明转座酶衍生基因PGBD5在哺乳动物大脑发育中的功能。研究采用小鼠模型和人类遗传学分析相结合的方法，发现PGBD5通过诱导有丝分裂后神经元DNA断裂和体细胞基因组重排，调控大脑皮层神经元（特别是谷氨酸能神经元）的基因表达，其缺陷会导致智力障碍、运动障碍和癫痫等神经发育异常。其创新性在于首次将一种进化保守的转座酶衍生基因与大脑发育过程中的程序性DNA断裂和体细胞基因组重塑直接联系起来，为理解神经发育障碍提供了新的分子机制视角。局限性在于研究主要基于小鼠模型，PGBD5诱导DNA断裂和重排的具体下游信号通路及其在人类大脑发育不同阶段的精确作用仍需进一步阐明。

---

## 26. 通过合成回路工程化细胞的单细胞封装实现按需癌症免疫治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41533781)
**期刊：** Science advances
**PMID：** 41533781
**DOI：** 10.1126/sciadv.aea3573

### 第一部分 原文与翻译

**英文原标题：** On-demand cancer immunotherapy via single-cell encapsulation of synthetic circuit-engineered cells.

> **英文摘要：**
> Despite the therapeutic potential of engineered immune cell therapy against metastases, it faces challenges including cytokine-driven systemic toxicity, off-target biodistribution, and host rejection. Here, we develop red/far-red light-regulated individually encapsulated (RL/FRL-EnE) cells, integrating optogenetics with biomaterial encapsulation for precise immunomodulation. This system uses a phytochrome A-based photoswitch (ΔPhyA-PCB) that enables bidirectional control. RL (660 nanometers) triggers interferon-γ, interleukin-6, and anti-CD47 expression via ΔPhyA-PCB-far-red elongated hypocotyl 1 heterodimerization, while FRL (740 nanometers) rapidly reverses production, minimizing toxicity. Single-cell nanoencapsulation prevents intercellular cross-talk and immune clearance, enabling strict light-dependent regulation and extended tumor residence. In vivo, RL/FRL-EnE cells remodeled the tumor microenvironment, reducing immunosuppressive myeloid cells (1.3- to 1.7-fold), while enhancing dendritic cell (1.4-fold) and CD8 T cell (2.8-fold) infiltration. Collectively, this work establishes a paradigm for closed-loop cellular immunotherapy, where light-regulated living therapeutics achieve on-demand immune reprogramming.

> **中文摘要：**
> 尽管工程化免疫细胞疗法在治疗转移瘤方面具有潜力，但它面临着包括细胞因子驱动的全身毒性、脱靶生物分布和宿主排斥在内的挑战。在此，我们开发了红/远红光调控的个体化封装（RL/FRL-EnE）细胞，将光遗传学与生物材料封装相结合，以实现精确的免疫调节。该系统使用基于光敏色素A的光开关（ΔPhyA-PCB），可实现双向控制。红光（660纳米）通过ΔPhyA-PCB与远红光伸长下胚轴1异源二聚化，触发干扰素-γ、白细胞介素-6和抗CD47的表达，而远红光（740纳米）则迅速逆转其产生，从而最小化毒性。单细胞纳米封装防止了细胞间串扰和免疫清除，实现了严格的光依赖性调控并延长了肿瘤驻留时间。在体内，RL/FRL-EnE细胞重塑了肿瘤微环境，减少了免疫抑制性髓系细胞（1.3至1.7倍），同时增强了树突状细胞（1.4倍）和CD8 T细胞（2.8倍）的浸润。总之，这项工作建立了一种闭环细胞免疫治疗的范式，其中光调控的活体治疗剂实现了按需的免疫重编程。

### 第二部分 AI 大师评价

本研究旨在解决工程化免疫细胞疗法面临的全身毒性、脱靶和排斥等挑战，其核心创新在于将光遗传学与单细胞生物材料封装技术融合，构建了一个可双向、按需调控的“活体”治疗系统。该方法通过红/远红光精确控制抗肿瘤免疫因子的表达与关闭，并结合封装技术隔离细胞、延长驻留，在动物模型中成功重塑了免疫抑制性的肿瘤微环境。该工作为开发安全、可控的闭环细胞疗法提供了新范式，但其临床转化潜力仍需在更大动物模型及人体中验证光穿透深度、长期安全性及封装材料的生物相容性。

---

## 27. 对健康达菲阴性成人绝对中性粒细胞计数和白细胞计数的多国评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41191521)
**期刊：** Blood
**PMID：** 41191521
**DOI：** 10.1182/blood.2025029359

### 第一部分 原文与翻译

**英文原标题：** Multinational assessment of absolute neutrophil counts and white blood cell counts among healthy Duffy-null adults.

> **英文摘要：**
> Laboratory reference intervals must reflect population diversity for accurate medical decisions. The Duffy-null variant lowers absolute neutrophil counts (ANC), but existing dedicated reference intervals are based on a single African American cohort. The impact across other ethnic groups and regions remains unclear, and no white blood cell count (WBC) intervals exist for Duffy-null individuals. This study aimed to establish and compare Duffy-null ANC and WBC reference intervals across 4 continents. A cross-sectional study was conducted assessing healthy Duffy-null individuals from dedicated cohorts (blood donors in Namibia, Saudi Arabia, and the United Kingdom; primary care patients in the United States) and biobanks (participants from the United Kingdom and the United States). Among 8018 participants (880 from dedicated cohorts and 7138 from biobanks), novel ANC and WBC reference intervals were established (Namibia [ANC, 820/μL to 6370/μL; WBC, 2.51 × 109/L to 9.85 × 109/L]; Saudi Arabia [ANC, 1140/μL to 5290/μL; WBC, 3.72 × 109/L to 10.71 × 109/L]; United Kingdom (ANC, 1185/μL to 5462/μL; WBC, 3.1 × 109/L to 8.8 × 109/L]; the United States [ANC, 1210/μL to 5390/μL; WBC, 3.00 × 109/L to 9.66 × 109/L]), with no significant differences between cohorts. Institutional reference intervals misclassified 27.9% (Namibia), 50.9% (Saudi Arabia), 26.0% (United Kingdom), and 21.7% (the United States) as neutropenic. Biobank analyses confirmed no significant difference in ANC between Black and non-Black Duffy-null participants. Duffy-null individuals consistently exhibit lower ANC and WBC across ethnic groups and regions. Current reference intervals overlook this variation, risking misdiagnosis and health inequities. Implementing Duffy-specific reference intervals is essential for equitable and accurate clinical decisions worldwide.

> **中文摘要：**
> 实验室参考区间必须反映人群多样性，以确保医疗决策的准确性。达菲阴性变异会降低绝对中性粒细胞计数，但现有的专门参考区间仅基于一个非裔美国人队列。该变异对其他种族群体和地区的影响尚不清楚，且目前没有针对达菲阴性个体的白细胞计数参考区间。本研究旨在建立并比较跨越四大洲的达菲阴性ANC和WBC参考区间。我们进行了一项横断面研究，评估了来自专门队列（纳米比亚、沙特阿拉伯和英国的献血者；美国的初级保健患者）和生物样本库（来自英国和美国的参与者）的健康达菲阴性个体。在8018名参与者中（880名来自专门队列，7138名来自生物样本库），建立了新的ANC和WBC参考区间（纳米比亚 [ANC，820/μL 至 6370/μL；WBC，2.51 × 109/L 至 9.85 × 109/L]；沙特阿拉伯 [ANC，1140/μL 至 5290/μL；WBC，3.72 × 109/L 至 10.71 × 109/L]；英国 [ANC，1185/μL 至 5462/μL；WBC，3.1 × 109/L 至 8.8 × 109/L]；美国 [ANC，1210/μL 至 5390/μL；WBC，3.00 × 109/L 至 9.66 × 109/L]），各队列间无显著差异。机构现行参考区间将27.9%（纳米比亚）、50.9%（沙特阿拉伯）、26.0%（英国）和21.7%（美国）的达菲阴性个体误判为中性粒细胞减少症。生物样本库分析证实，黑人与非黑人达菲阴性参与者的ANC无显著差异。达菲阴性个体在不同种族和地区均表现出较低的ANC和WBC。当前的参考区间忽视了这种变异，存在误诊和健康不公平的风险。在全球范围内实施针对达菲阴性的特异性参考区间，对于实现公平和准确的临床决策至关重要。

### 第二部分 AI 大师评价

本研究旨在解决达菲阴性个体因缺乏特异性参考区间而面临的临床误诊风险。研究创新性地通过横断面设计，整合了四大洲专门队列与生物样本库数据，首次建立了多国达菲阴性人群的ANC和WBC参考区间。核心发现是，达菲阴性个体的ANC和WBC普遍低于常规参考范围，且现行标准会导致高达50.9%的误判，这凸显了实施种族特异性参考区间的紧迫性。研究的局限性在于其横断面设计无法确定因果关系，且部分区域样本可能未完全代表所有亚群，但其大规模多中心数据为全球临床实践标准化提供了关键证据。

---

## 28. 多选择性RAS(ON)抑制剂靶向致癌性RAS并克服急性髓系白血病中RAS介导的FLT3抑制剂和BCL2抑制剂耐药。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41144772)
**期刊：** Blood
**PMID：** 41144772
**DOI：** 10.1182/blood.2025030558

### 第一部分 原文与翻译

**英文原标题：** Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.

> **英文摘要：**
> Aberrant activation of RAS/MAPK signaling limits the clinical efficacy of several targeted therapies in acute myeloid leukemia (AML). In FMS-like tyrosine kinase-3 (FLT3)-mutant AML, the selection of clones harboring heterogeneous RAS mutations drives resistance to FLT3 inhibitors (FLT3i). RAS activation is also associated with resistance to other AML targeted therapies, such as the B-cell lymphoma 2 inhibitor venetoclax. Despite the critical need to inhibit RAS/MAPK signaling in AML, no targeted therapies have demonstrated a临床 benefit in RAS-driven AML. To address this unmet need, we investigated the preclinical activity of RMC-7977, a multiselective inhibitor of GTP-bound active (RAS[ON]) isoforms of mutant and wild-type RAS in AML models. RMC-7977 exhibited potent antiproliferative and proapoptotic activity across AML cell lines with MAPK-activating signaling mutations. In cell line models with acquired FLT3i resistance because of secondary RAS mutations, treatment with RMC-7977 restored sensitivity to FLT3i. Similarly, RMC-7977 effectively reversed resistance to venetoclax in RAS-addicted cell line models with both RAS wild-type and mutant genetic backgrounds. In murine patient-derived xenograft models of RAS-mutant AML, RMC-7977 was well tolerated and significantly suppressed leukemic burden in combination with gilteritinib or venetoclax. Our findings strongly support clinical investigation of broad-spectrum RAS(ON) inhibition in AML to treat and potentially prevent drug resistance because of activated RAS signaling.

> **中文摘要：**
> RAS/MAPK信号通路的异常激活限制了多种靶向疗法在急性髓系白血病（AML）中的临床疗效。在FMS样酪氨酸激酶-3（FLT3）突变的AML中，携带异质性RAS突变的克隆选择驱动了对FLT3抑制剂（FLT3i）的耐药性。RAS激活也与其他AML靶向疗法的耐药相关，例如B细胞淋巴瘤2抑制剂维奈克拉。尽管在AML中抑制RAS/MAPK信号通路的需求迫切，但尚无靶向疗法在RAS驱动的AML中显示出临床获益。为解决这一未满足的需求，我们在AML模型中研究了RMC-7977的临床前活性，RMC-7977是一种针对突变型和野生型RAS的GTP结合活性形式（RAS[ON]）的多选择性抑制剂。RMC-7977在具有MAPK激活信号突变的AML细胞系中表现出强大的抗增殖和促凋亡活性。在因继发性RAS突变而获得FLT3i耐药性的细胞系模型中，RMC-7977治疗恢复了对FLT3i的敏感性。类似地，在具有RAS野生型和突变型遗传背景的RAS成瘾细胞系模型中，RMC-7977有效逆转了对维奈克拉的耐药性。在RAS突变AML的小鼠患者来源异种移植模型中，RMC-7977耐受性良好，并与吉瑞替尼或维奈克拉联用显著抑制了白血病负荷。我们的研究结果有力地支持了在AML中对广谱RAS(ON)抑制进行临床研究，以治疗并可能预防由激活的RAS信号通路引起的耐药性。

### 第二部分 AI 大师评价

本研究旨在解决AML中RAS/MAPK通路异常激活导致的靶向治疗耐药这一关键临床难题。研究者采用了一种创新的多选择性RAS(ON)抑制剂RMC-7977，该药能同时靶向突变型和野生型RAS的活性形式。核心发现是RMC-7977在临床前模型中不仅能直接抑制RAS驱动的AML细胞生长，还能有效逆转由RAS介导的对FLT3抑制剂和BCL2抑制剂的获得性耐药，并与现有药物联用显示出协同抗白血病效应。其创新性在于提供了克服多种靶向药耐药的新策略，但研究仍处于临床前阶段，其人体安全性、疗效及长期耐药风险尚待临床试验验证。

---

## 29. CPX-351治疗唐氏综合征相关髓系白血病：来自III期ML-DS 2018试验的结果与预后因素。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41118594)
**期刊：** Blood
**PMID：** 41118594
**DOI：** 10.1182/blood.2025030775

### 第一部分 原文与翻译

**英文原标题：** CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.

> **英文摘要：**
> Myeloid leukemia of Down syndrome (ML-DS) is associated with an excellent prognosis but high treatment-related toxicity and mortality. The Phase 3 Clinical Trial for CPX-351 in ML-DS 2018 aimed to maintain the excellent event-free survival (EFS) achieved in the previous ML-DS 2006 trial while reducing the treatment intensity. Intensity-reduced induction and reinduction therapy with cytarabine and idarubicin with or without etoposide was replaced with CPX-351 (66 U/m2 on 3 days in course 1 and on 2 days in course 2). Risk stratification was based on flow cytometric measurable residual disease (MRD) after first induction. High-risk patients received high-dose cytarabine (3 g/m2 per 12 hour) in consolidation; standard-risk patients received cytarabine at a dose of 1 g/m2 per 12 hour. A total of 35 patients were enrolled until the trial was halted because of an unexpectedly high relapse rate. A per-protocol interim analysis revealed a significantly lower 24-month EFS when compared with the ML-DS 2006 trial (69% vs 90%; P< .001). In contrast with previous studies, most patients who relapsed responded to salvage therapy, leading to a comparable 24-month overall survival of 88% (vs 92%; P = .612). CPX-351 demonstrated a favorable toxicity profile with no treatment-related mortality. Positive MRD by error-corrected GATA1 next-generation sequencing, the presence of trisomy 8 or a complex karyotype were associated with an increased risk for relapse. In conclusion, replacing intensity-reduced induction therapy with CPX-351 in ML-DS led to a significantly lower EFS, highlighting the need for dose optimization to balance the efficacy and toxicity in this sensitive patient population. This trial was registered at https://www.clinicaltrialsregister.eu as EudraCT #2018-002988-25.

> **中文摘要：**
> 唐氏综合征髓系白血病（ML-DS）预后良好，但治疗相关毒性和死亡率高。ML-DS 2018试验中CPX-351的III期临床试验旨在维持先前ML-DS 2006试验所实现的优异无事件生存率（EFS），同时降低治疗强度。研究将强度减低的、含或不含依托泊苷的阿糖胞苷和伊达比星的诱导及再诱导方案，替换为CPX-351（第1疗程给药3天，第2疗程给药2天，剂量为66 U/m2）。风险分层基于首次诱导后的流式细胞术可测量残留病（MRD）。高危患者在巩固治疗阶段接受大剂量阿糖胞苷（每12小时3 g/m2）；标危患者接受阿糖胞苷（每12小时1 g/m2）。该试验共入组35例患者，后因复发率意外升高而提前终止。一项符合方案集的中期分析显示，与ML-DS 2006试验相比，24个月EFS显著降低（69% vs 90%；P < .001）。与既往研究不同，大多数复发患者对挽救治疗有反应，从而获得了可比的24个月总生存率（88% vs 92%；P = .612）。CPX-351显示出良好的毒性特征，无治疗相关死亡。通过错误校正的GATA1二代测序检测到的MRD阳性、存在8号染色体三体或复杂核型与复发风险增加相关。总之，在ML-DS中用CPX-351替代强度减低的诱导治疗导致了显著更低的EFS，这凸显了在这一敏感患者群体中需要优化剂量以平衡疗效与毒性。本试验已在https://www.clinicaltrialsregister.eu注册，EudraCT编号为#2018-002988-25。

### 第二部分 AI 大师评价

本研究是一项旨在优化ML-DS治疗的III期临床试验，核心目的是验证在降低治疗强度的前提下，用脂质体CPX-351方案替代传统化疗能否维持优异的EFS。研究创新性地采用了基于流式MRD的风险分层指导巩固治疗，并探索了新型分子标志物（如GATA1突变）的预后价值。主要发现是CPX-351方案虽安全性良好，但未能维持既往方案的EFS优势，导致试验提前终止，这揭示了在该敏感人群中疗效与减毒之间的精细平衡极具挑战性。研究局限性在于因提前终止导致样本量有限，且未能明确CPX-351疗效不足的具体机制，为未来剂量优化研究指明了方向。

---

## 30. 使用新一代测序对新诊断多发性骨髓瘤患者的高危基因组共识定义进行验证

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991836)
**期刊：** Blood
**PMID：** 40991836
**DOI：** 10.1182/blood.2025029999

### 第一部分 原文与翻译

**英文原标题：** High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

> **英文摘要：**
> The prognostic heterogeneity of multiple myeloma is mainly driven by the genomic features of myeloma cells. The International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) recently proposed a high-risk (HR) genomic model to have a consensus definition of genomic risk. We performed next-generation sequencing in the form of a panel on samples from 6528 patients with newly diagnosed multiple myeloma (NDMM) and 1583 patients at first relapse between 2019 and 2024. We observed that 22.4% of patients at diagnosis and 36.7% of patients at first relapse were classified as high risk according to the Consensus Genomic Staging. Clinical data were available for 2695 patients at diagnosis. After a median follow-up of 35 months, the median progression-free survival (PFS) was 30 months for patients with HR NDMM and 51 months for standard-risk (SR) patients (P< .0001). The HR cytogenetic criteria from the Revised- International Staging System score were not able to differentiate between HR and SR patients based on the IMS/IMWG genomic subgroups. Looking at each criterion independently, we found that the presence of del(17p), TP53 mutation, biallelic del(1p32), or the combination of intermediate-risk cytogenetics (gain 1q, del(1p32), t(4;14), t(14;16), t(14;20)) significantly reduced the PFS when compared with SR patients. Moreover, patients with several cumulating criteria had an even worse prognosis. Among SR patients, classified according to the genomic definition with normal creatinine, the median PFS for those with high β2-microglobulin was not significantly different from that of patients with normal β2-microglobulin level. This study validated the IMS/IMWG genomic definition of HR myeloma in a large cohort of patients diagnosed from 2019 onwards.

> **中文摘要：**
> 多发性骨髓瘤的预后异质性主要由骨髓瘤细胞的基因组特征驱动。国际骨髓瘤协会（IMS）/国际骨髓瘤工作组（IMWG）最近提出了一个高危（HR）基因组模型，以期对基因组风险达成共识定义。我们对2019年至2024年间6528例新诊断多发性骨髓瘤（NDMM）患者和1583例首次复发患者的样本进行了基于测序组合的新一代测序。我们观察到，根据共识基因组分期，22.4%的诊断时患者和36.7%的首次复发时患者被归类为高危。2695例诊断时患者可获得临床数据。中位随访35个月后，HR NDMM患者的中位无进展生存期（PFS）为30个月，而标危（SR）患者为51个月（P< .0001）。修订的国际分期系统评分中的HR细胞遗传学标准无法基于IMS/IMWG基因组亚组区分HR和SR患者。独立观察每个标准时，我们发现，与SR患者相比，存在del(17p)、TP53突变、双等位基因del(1p32)或中危细胞遗传学（1q增益、del(1p32）、t(4;14)、t(14;16)、t(14;20)）的组合显著降低了PFS。此外，具有多个累积标准的患者预后更差。在根据基因组定义归类为SR且肌酐正常的患者中，高β2-微球蛋白患者的中位PFS与β2-微球蛋白水平正常患者相比无显著差异。本研究在一个自2019年起诊断的大型患者队列中验证了IMS/IMWG对高危骨髓瘤的基因组定义。

### 第二部分 AI 大师评价

本研究旨在利用大规模队列数据，验证国际骨髓瘤协会/工作组提出的高危多发性骨髓瘤基因组共识定义的临床实用性。研究通过对超过8000例患者进行新一代测序，证实了该共识分期的预后分层能力，并明确了del(17p)、TP53突变等关键基因组异常与不良预后的关联。其创新性在于首次在大型前瞻性队列中系统验证了该共识模型，并揭示了传统细胞遗传学高危标准在基因组亚组中的局限性。然而，研究的中位随访时间（35个月）相对有限，可能不足以完全评估长期生存差异，且分析主要基于测序组合，可能遗漏全基因组层面的复杂变异信息。

---

速递结束，祝您工作愉快！